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Introduction		The	improvements	in	healthcare	over	the	last	century	have	resulted	in	increased	demographic	aging	over	time.	Today’s	generation’s	average	lifespan	is	approximately	four	years	longer	than	that	of	their	parents’,	a	trend	that	is	predicted	to	continue.	Since	the	world	population	has	a	greater	proportion	of	older	 individuals,	 the	number	of	neurodegenerative	diseases	has	 also	 increased.	To	date,	 idiopathic	Parkinson’s	Disease	 (PD)	 is	 the	 second	most	 common	neurodegenerative	 disease	 in	 Europe,	with	 a	prevalence	of	1.8%	at	the	age	of	55	(de	Rijk	et	al.,	1997).	The	risk	of	PD	is	associated	with	age	and	the	prevalence	after	the	age	of	65	doubles	nearly	every	five	years	(de	Rijk	et	al.,	1995).	Therefore,	by	the	year	2030	PD	will	probably	 increase	by	25%	relative	 to	2005	(Winge,	Friberg,	Werdelin,	Nielsen,	&	Stimpel,	2005),	dramatically	affecting	health	care	costs	and	patients	quality	of	 life	(Martinez-Martin,	Rodriguez-Blazquez,	Kurtis,	Chaudhuri,	&	Group,	2011).			Parkinson’s	Disease	is	characterized	by	its	motor	symptoms:	resting	tremor,	rigidity	and	bradykinesia,	which	are	caused	by	loss	of	neurons	in	the	substantia	nigra	and	Lewy	bodies	in	the	surviving	neurons	(Halliday,	Hely,	Reid,	&	Morris,	2008).	In	addition	to	the	cardinal	symptoms,	non-motor	impairments,	such	as	autonomic	failure,	cognitive	worsening	or	psychiatric	symptoms	often	occur	during	the	course	of	disease,	representing	a	significant	burden	of	PD	patients	by	lowering	their	health-	related	quality	of	life	 (HRQoL)	 (Martinez-Martin,	 Rodriguez-Blazquez,	 et	 al.,	 2011)	 and	 contributing	 to	 the	 disease	progression	(Antonini	et	al.,	2012;	Khoo	et	al.,	2013).		One	 of	 the	most	 bothersome	 non-motor	 symptoms,	 as	well	 for	 patients	 as	 for	 their	 caregivers,	 are	urinary	symptoms.	Studies	show	that	bladder	problems	have	a	considerable	negative	impact	on	quality	of	life,	lead	to	early	institutionalization	and	higher	health	costs	(Araki,	Kitahara,	Oida,	&	Kuno,	2000;	Rahman,	 Griffin,	 Quinn,	&	 Jahanshahi,	 2008).	 The	 prevalence	 of	 bladder	 dysfunction	 is	 significantly	higher	 among	 PD	 patients,	when	 compared	 to	 the	 healthy	 individuals	 (HI)	 of	 the	 same	 age	 (Badri,	Purohit,	Skenazy,	Weiss,	&	Blaivas,	2014).	Even	though,	urinary	symptoms	might	appear	throughout	the	course	 of	 the	 disease,	 even	 preceding	 motor	 symptoms,	 the	 prevalence	 rises	 among	 patients	 who	experience	dementia	and	in	late	stages	of	the	disease	(Miyasaki,	2016;	Winge	&	Nielsen,	2012).			There	seems	to	be	no	agreement	on	the	origin	of	the	urinary	problems	in	PD	(PD-UU).	The	conservative	view	of	urinary	problems	does	not	assign	them	to	the	degenerative	processes	of	dopaminergic	neurons	in	the	substantia	nigra	(Sakakibara	et	al.,	2014),	however	neuroimaging	studies	have	revealed	further	insight	concerning	the	regulation	of	micturition	in	both,	healthy	subjects	and	PD	patients,	showing	the	involvement	 of	 several	 cortical	 and	 subcortical	 structures,	 such	 as	 basal	 ganglia,	 thalamus,	 anterior	cingulate	cortex	and	prefrontal	cortex	(Fowler,	Griffiths,	&	de	Groat,	2008;	Fowler	&	Griffiths,	2010;	
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Griffiths	&	Fowler,	2013).	Interestingly,	 in	PD,	degenerative	processes	can	be	found	in	most	of	these	cortical	structures	(Fowler,	1999;	Fowler	et	al.,	2008).	Generally,	bladder	problems	have	been	divided	into	storage	and	voiding	symptoms,	dependent	on	both,	sacral	autonomic	reflex	and	brain	regions,	such	as	 the	pontine	 center,	 hypothalamus,	 basal	 ganglia,	 frontal	 cortex	 (de	Groat,	Griffiths,	&	Yoshimura,	2015;	Fowler	et	al.,	2008;	Griffiths	&	Fowler,	2013;	Yoshimura	&	de	Groat,	1997).	The	difficulties	of	distinguishing	between	age-related	changes	of	micturition	and	neurodegenerative	symptoms	originate	from	the	age	group	of	PD	patients.	Men	over	60	years	of	age	might	experience	bladder	symptoms	as	a	result	 of	 prostate	 hyperplasia,	 whereas	 women	 might	 experience	 stress	 urinary	 incontinence,	 or	impairments	 connected	 to	birth.	The	prevalence	 rates	 vary	between	studies,	 as	 some	of	 them	were	published	 before	 the	 diagnosis	 of	 multiple	 system	 atrophy	 (Gilman	 et	 al.,	 1999).	 Furthermore,	 the	influence	 of	 dopaminergic	 treatment	 on	 the	 bladder	 is	 not	 well	 understood	 and	 rather	 random	(Uchiyama,	 Sakakibara,	 Hattori,	 &	 Yamanishi,	 2003).	 In	 addition	 to	 the	 above-mentioned	 factors,	prevalence	 of	 UD	 among	 PD	 patients	 has	 its	 onset	mostly	 after	 the	 appearance	 of	motor	 disorder.	Additionally,	the	variation	of	prevalence	and	appearance	might	reflect	the	methodology	used	to	assess	the	symptoms	and	reflects	differences	in	patient	population	(McDonald,	Winge,	&	Burn,	2017).	Although	bladder	 symptoms	 can	 appear	 throughout	 the	 course	 of	 the	 disease,	 PD-UU	 seems	 to	 be	 a	 late	manifestation	and	correlates	with	incidence	of	other	non-motor	symptoms	with	its	peak	at	the	state	of	dementia	 (Khoo	 et	 al.,	 2013;	McDonald	 et	 al.,	 2017).	 To	 date,	 the	 association	 between	 urinary	 and	cognitive	function	has	only	been	investigated	sparsely,	even	though	the	role	of	prefrontal	cortex	in	PD-UU	has	been	accepted	(Kitta,	Chancellor,	de	Groat,	Shinohara,	&	Yoshimura,	2016;	Kitta	et	al.,	2006;	Kitta	et	al.,	2015).	Furthermore,	the	association	between	motor	symptoms,	disease	severity,	other	non-motor	symptoms	 and	 cognitive	 impairment	 have	 been	 documented	 (Kadastik-Eerme,	 Rosenthal,	 Paju,	Muldmaa,	&	Taba,	2015;	McDonald	et	al.,	2017;	Moriarty,	Robinson,	Bunting-Perry,	&	Bradway,	2016;	Picillo	et	al.,	2017;	Sakakibara	et	al.,	2014;	Skorvanek	et	al.,	2015).	The	close	connection	of	cognitive	worsening	 and	 urinary	 dysfunction	 has	magnified	 the	 need	 to	 characterize	 those	 PD	 patients,	with	cognitive-driven	urinary	dysfunction,	which	was	the	main	focus	of	this	doctoral	thesis.			The	second	research	motivation	for	this	thesis	was	to	improve	early	detection	of	cognitive	deterioration	in	PD.	A screening tool, often used in a clinical daily routine is Montreal Cognitive Assessment (MoCA) (Nasreddine 
et al., 2005). Developed	 for	 Alzheimer’s	Disease	 (AD)	 patients,	 the	MoCA	 has	 also	 become	 the	 go-to	screening	 tool	 for	 PD	patients,	 as	 it	 focuses	 on	 the	 executive	 functions,	 the	main	 drive	 of	 cognitive	deterioration	 in	 PD	 (Dirnberger & Jahanshahi, 2013). However, studies show that the course of cognitive 
impairment is different for PD than AD patients (Fengler et al., 2016). Therefore,	our	primary	objective	was	the	validation	of	a	scoring	algorithm,	which	would	improve	the	MoCA’s	psychometric	accuracy	in	PD.	An	 early	 diagnosis	 of	 cognitive	 impairment	 in	 PD	 is	 considered	 to	 be	 of	 high	 importance,	 since	therapeutic	 measures	 are	 effective,	 especially	 in	 the	 early	 stages	 of	 neurodegeneration	 (Olanow	 &	Obeso,	2012).	Possible	neuroprotective	approaches	can	be	indicated	only	when	the	subgroup	of	patients	is	correctly	diagnosed.	Therefore,	it	is	important	to	identify	reliable,	objectively	measurable	tool	that	detects	 early	 symptoms	 of	 PD	Mild	 cognitive	 impairment	 (PD-MCI)	 that	 narrow	 a	 risk	 group	 of	 PD	Dementia	(PDD). 
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The	aim	of	this	thesis	was	to	evaluate	the	link	between	cognition	and	PD-UU.	We	broadly	investigated	cognitive	functions	and	other	non-motor	aspects,	which	allowed	us	to	identify	a	subgroup	of	PD	patients	whose	 urinary	 problems	 may	 have	 been	 caused	 and/or	 worsened	 by	 accompanied	 cognitive	impairment.	In	the	final	step,	we	validated	a	new	scoring	algorithm	for	a	sensitive,	economic	cognitive	test	battery,	which	has	been	only	sparsely	investigated	in	a	non-demented	PD	population,	in	order	to	improve	diagnostic	tools	used	in	a	clinical	every	day	routine.			
	Parkinson’s	Disease		PD	 is	 a	 progressive	 neurodegenerative	 movement	 disorder,	 which	 is	 characterized	 by	 its	 motor	symptoms:	resting	tremor,	rigidity	and	bradykinesia.	PD	is	the	second	most	common	neurodegenerative	disorder,	with	a	prevalence	of	1.8%	in	the	general	population	for	subjects	of	55	years	of	age,	or	older	(de	Rijk	et	al.,	2000).	The	prevalence	of	PD	increases	with	an	individual’s	age	and	is	more	common	for	people	of	European	decent	as	opposed	to	Asian	(Pringsheim,	Jette,	Frolkis,	&	Steeves,	2014).			The	motor	 symptoms	of	PD	are	caused	by	 the	neurodegenerative	processes	of	 substantia	nigra	and	presence	of	Lewy	Bodies	in	brain	cells.	The	degenerative	processes	are	linked	to	synuclein	pathology	with	 Lewy	 neurites	 and	 interneuronal	 Lewy	 bodies	 in	 sympathetic	 ganglia	 and	 the	 peripheral	autonomic	nervous	system	(Berg	et	al.,	2014).	Furthermore,	changes	in	the	central	parts	of	autonomic	system	as	well	 as	 the	dorsal	 vagal	nucleus,	 the	hypothalamus	and	 the	 spinal	 cord	 contribute	 to	 the	pathology	(Braak,	Ghebremedhin,	Rub,	Bratzke,	&	Del	Tredici,	2004;	Hughes,	Daniel,	Blankson,	&	Lees,	1993;	van	der	Heeden,	Marinus,	Martinez-Martin,	&	van	Hilten,	2016),	causing	additional	non-motor	problems.			Motor	 symptoms	 are,	 however,	 insufficient	 to	 subtype	 PD	 patients.	 PD	 varies	 in	 its	 clinical	manifestations,	 and	 therefore	 has	 been	 divided	 into	 subtypes.	 The	 classification	 is	 based	 on	 the	heterogeneous	symptoms	of	the	disease:	clinical-	with	motor	Parkinsonism,	prodromal-motor,	or	non-	motor	 symptoms	 present	 and	 preclinical-	 when	 neurodegeneration	 is	 present,	 but	 asymptomatic	(Postuma	et	al.,	2015).	Clinicopathological	criteria,	considering	motor	progression	lead	to	the	tremor-dominant	and	akinetic-rigid	subtyping,	taking	motor,	non-motor	and	cognitive	symptoms	into	account	(Berg	et	al.,	2014;	Jankovic	&	Kapadia,	2001).	Recently,	a	new	subtype	of	more	diffuse	progression	has	been	proposed	 (Fereshtehnejad	et	 al.,	 2015).	However,	 even	with	 this	 approach,	 classifying	PD	 into	subtypes	is	not	yet	fully	expended.			The	non-motor	aspects	include	autonomic	symptoms,	such	as	orthostatic	hypotension	(Damon-Perriere	et	 al.,	 2012),	 bladder	 dysfunction	 (Picillo	 et	 al.,	 2017),	 or	 sexual	 dysfunction	 (Pfeiffer,	 2010);	 sleep	disturbances	 (Grover,	 Somaiya,	 Kumar,	 &	 Avasthi,	 2015);	 gastrointestinal	 symptoms	 (Barone	 et	 al.,	2009);	 cognitive	 impairment	 (Aarsland,	 2016),	 or	 neuropsychiatric	 disorders,	 such	 as	 depression,	
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anxiety	 or	 apathy	 (Grover	 et	 al.,	 2015;	 Sveinbjornsdottir,	 2016).	 Even	 though,	 some	 autonomic	symptoms,	such	as	orthostatic	hypotension,	or	aspects	of	gastrointestinal	tract	have	been	associated	with	 dopaminergic	 peripheral	 degenerative	 processes,	 most	 symptoms	 result	 from	 the	 non-dopaminergic	pathological	mechanisms	(Chaudhuri,	2006).			The	motor	as	well	as	non-motor	symptoms	develop	progredient,	and	their	initial	onset	can	precede	the	clinical	 diagnosis	 of	 PD.	 Almost	 90%	 of	 all	 patients	 report	 to	 have	 experienced	 some	 unspecific	symptoms,	years	before	PD	was	diagnosed	(Goldman	&	Postuma,	2014).	Retrospectively,	over	98%	of	all	patients,	report	up	to	six	symptoms,	such	as	loss	of	smell,	up	to	20	years	prior	the	initial	diagnosis	of	PD	(Gaenslen,	Swid,	Liepelt-Scarfone,	Godau,	&	Berg,	2011).	During	the	course	of	the	disease,	almost	all	patients	(98.6%)	report	about	at	least	one	non-motor	symptom	(Barone	et	al.,	2009).	The	non-motor	symptoms	are	mostly	being	diagnosed	by	using	validated	questionnaires	and	scales	(Chaudhuri,	Healy,	Schapira,	 &	 National	 Institute	 for	 Clinical,	 2006;	 Chaudhuri,	 Martinez-Martin,	 et	 al.,	 2006).	 It	 is	important	 to	 emphasize,	 that	 non-motor	 symptoms	 contribute	 to	 the	 disease	 progression	(Fereshtehnejad	et	al.,	2015)	and	have	the	biggest	impact	on	the	worsening	of	patients’	quality	of	life,	with	PD-UU	being	one	of	the	most	frequent	ones	(Berganzo	et	al.,	2016;	Kadastik-Eerme	et	al.,	2015;	Prakash,	Nadkarni,	Lye,	Yong,	&	Tan,	2016).	
	
	
Bladder	Symptoms	in	Parkinson’s	Disease		The	 prevalence	 of	 the	 urinary	 symptoms	 in	 PD	 ranges	 by	 about	 27-39%,	 based	 on	 validated	questionnaires	(Araki	&	Kuno,	2000;	Campos-Sousa	et	al.,	2003)	and	is	significantly	higher	than	in	HI,	similar	in	age	and	gender.	Bladder	symptoms	are	classified	in	irritative,	obstructive	or	mixed	symptoms.	Frequency,	urgency	and	nocturia	are	irritative	symptoms	caused	by	hyperactivity	of	the	bladder,	mostly	due	 to	 detrusor	 hyperreflexia	 (McDonald	 et	 al.,	 2017).	 Incomplete	 emptying,	 intermittence,	 weak	urinary	stream	and	hesitation	are	called	obstructive	symptoms	and	can	appear	as	a	result	of	bladder	hypoactivity.			The	most	common	urinary	symptoms	in	PD	are	nocturia,	 frequency,	urgency,	and	urge	 incontinence	(McDonald	et	al.,	2017;	Zhang	&	Zhang,	2015).	The	prevalence	of	urinary	symptoms	 is	27%	to	39%	(Araki	&	Kuno,	2000;	Campos-Sousa	et	al.,	2003)	when	based	on	a	validated	questionnaire,	while	it	is	over	40%	(Yamamoto	et	al.,	2009)	or	even	up	to	60%	(Hattori,	Yasuda,	Kita,	&	Hirayama,	1992),	when	using	a	non-validated	questionnaire.	Urodynamic	evaluation	confirmed	abnormalities	in	36%	to	90%	of	patients,	which	consist	of	detrusor	hyperreflexia	with	or	without	complete	relaxation	of	the	pelvic	floor	musculature	and	sphincter	during	micturition	 (Andersen,	1985;	Berger,	Blaivas,	DeLaRocha,	&	Salinas,	1987).		
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Even	though,	PD-UU	might	appear	throughout	the	course	of	the	disease,	the	prevalence	rises	especially	in	the	late	stages	of	PD	(Uchiyama	et	al.,	2011;	Winge	&	Nielsen,	2012),	with	a	median	onset	around	12	years	after	PD	diagnosis	(Wenning	et	al.,	1999).	The	influence	of	PD-UU	on	daily	life	is	very	complex.	Bladder	questionnaires	that	examine	“bother”,	or	influence	on	activities	of	daily	living	(ADL),	show	that	symptoms	that	worry	PD	patients	the	most	are	overactive	bladder	and	urinary	incontinence	(McDonald	et	al.,	2017;	Winge	&	Fowler,	2006).	The	association	between	ADL	and	PD-UU,	however,	changes	as	the	PD	progresses	and	advances	with	the	disease	duration	(Berganzo	et	al.,	2016;	Kadastik-Eerme	et	al.,	2015;	Moriarty	et	al.,	2016;	Ogawa	et	al.,	2017).	The	connection	between	PD-UU	and	motor-	as	well	as	other	non-motor	functions,	has	been	studied	in	the	last	years.	However,	it	is	difficult	to	distinguish	to	what	extend	PD-UU	is	influenced	by	neurodegenerative	processes,	motor	symptoms,	or	deteriorating	cognitive	functions.		Functional	neuroimaging	studies	in	HI	have	increased	the	understanding	of	the	micturition	reflex,	which	seems	 to	 be	under	 the	 control	 of	 several	 cortical	 and	 subcortical	 areas,	 including	 the	basal	 ganglia,	thalamus,	 insular	 cortex,	 anterior	 cingulate	 cortex	 and	 prefrontal	 cortex	 (Fowler	 et	 al.,	 2008;	Sakakibara,	Haruta,	et	al.,	2012;	Sakakibara,	Tateno,	et	al.,	2012).	It	is	important	to	mention,	that	in	PD,	most	of	these	cortical	structures	undergo	the	neurodegenerative	process	throughout	the	course	of	the	disease	(Braak	et	al.,	2004;	Hawkes,	Del	Tredici,	&	Braak,	2010).	As	basal	ganglia	seem	to	suppress	the	micturition	 reflex	 (Sakakibara,	 Uchiyama,	 Yamanishi,	 &	 Kishi,	 2010),	 logically,	 the	 deep	 brain	stimulation	of	the	subthalamic	nucleus	has	been	associated	with	improved	PD-UU	symptoms	(Winge	et	al.,	2007),	through	the	modulation	of	the	afferent	bladder	information	processing		(Herzog	et	al.,	2008).	Moreover,	frontal	lesions	following	stroke,	or	trauma	have	been	long	recognized	to	be	associated	with	urinary	symptoms,	as	the	prefrontal	cortex	has	been	shown	to	be	activated	during	bladder	filling	(Kitta	et	al.,	2006;	Kitta	et	al.,	2015).			Taking	into	account	the	age	of	most	PD	patients,	bladder	emptying	and/or	continence	may	be	influenced	by	other	prior	conditions,	such	as	prostatic	enlargement	in	men,	or	stress	incontinence	in	women	(Winge	et	al.,	2007).	 It	may	also	appear	as	a	consequence	either	of	neurodegenerative	processes,	or	the	given	treatment	(Kitta	et	al.,	2015;	Uchiyama	et	al.,	2003).	Patients	themselves	often	conceal	urinary	symptoms,	since	they	link	it	to	the	negative	side	effect	of	aging,	rather	than	to	the	neurological	disorder	(Zhang,	Gu,	An,	Wang,	 &	 Chan,	 2014;	 Zhang	 &	 Zhang,	 2015).	 Taking	 these	 facts	 into	 consideration	 and	 the	 high	prevalence	of	PD-UU,	it	is	of	a	great	importance	to	improve	diagnosis	and	the	treatment	of	PD-UU.	
	
 
Parkinson’s	Disease	and	Cognition		Cognitive	impairment	is	one	of	the	most	frequent	non-motor	symptoms	in	PD	and	has	been	qualified	by	patients	as	a	syndrome	of	a	high	distress	(Herman	et	al.,	2015;	Litvan	et	al.,	2012).	Moreover,	the	point-prevalence	of	PDD	is	between	24%	to	31%	among	PD	patients	and	usually	develops	after	10	years	after	
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PD	onset	(Aarsland,	2016;	Aarsland,	Hutchinson,	&	Larsen,	2003).	Dementia	has	severe	consequences	for	PD	patients,	which	includes	higher	mortality,	nursing	home	placement,	high	distress	and	more	rapid	motor	and	functional	decline	(Kawada,	Anang,	&	Postuma,	2015).			About	 27%	 of	 PD	 patients	 experience	 PD-MCI,	 which	 is	 characterized	 by	 clinical,	 cognitive	 and	functional	decline	(Litvan	et	al.,	2012).	PD-MCI	has	been	associated	with	higher	risk	of	developing	PDD	(Dubois	et	al.,	2007),	diagnosed	in	up	to	80%	of	PD	patients	during	the	longstanding	disease	course.			In	 2012,	 the	 Movement	 Disorder	 Society	 published	 criteria	 that	 enable	 a	 partially	 standardized	diagnosis	of	 the	PD-MCI.	However,	no	recommendation	of	 the	assessment	cut-off	has	been	released,	with	regard	to	cognitive	assessments.	In	the	literature,	PD-MCI	prevalence	rates	are	based	on	a	cut-off	below	1,	1.5	or	2	SD	from	the	mean	of	a	reference	group	of	mostly	HI.	It	means,	that	cognitive	disorder	can	be	diagnosed	when	84%,	93%	or	 98%	of	 the	normal	 population	has	 a	 better	 test	 performance	(Foltynie,	Brayne,	Robbins,	&	Barker,	2004;	Janvin,	Larsen,	Aarsland,	&	Hugdahl,	2006).	According	to	the	MDS	Task	Force	recommendations	severe	impairment	of	ADL	is	a	cardinal	symptom	differentiating	PD-MCI	and	PDD	patients	(Dubois	et	al.,	2007;	Litvan	et	al.,	2012).			Not	every	PD	patient	will	develop	PDD.	Regarding	cognitive	impairment,	recent	studies	have	revealed	a	substantial	heterogeneity	with	different	 severity,	 ranging	 from	minor	 cognitive	deteriorations	up	 to	fully	 developed	PDD.	One	of	 the	 earliest	 cognitive	domains	 that	 suffer	 functional	 impairment	 is	 the	executive	function	(Williams-Gray	et	al.,	2009),	which	has	been	reported	to	be	predictive	for	later	PDD	(Janvin	et	al.,	2006).	Frontal	deficits	are	common	in	PD.	Almost	70%	of	PD	patients	without	dementia	experience	deteriorating	deficits	 in	 cognitive	 functions	 (Janvin,	Aarsland,	 Larsen,	&	Hugdahl,	 2003).	Executive	 dysfunction	 includes	 deficits	 in	 controlling	 mental	 processes,	 cognitive	 flexibility	 and	problems	 solving,	 planning,	 or	 regulating	 complex	behaviors	 and	emotions	 (Emre,	 2003).	 Executive	dysfunction	of	PD	patients	is	characterized	by	the	loss	of	inhibitory	control	(Dirnberger	&	Jahanshahi,	2013),	 especially,	 within	 executive	 control	 tasks,	 that	 require	 inhibition	 of	 habitual	 or	 prepotent	responses	for	selection	of	appropriate	responses.			Executive	functions	are	the	main	drive	of	cognitive	deterioration	in	PD	(Aarsland,	2016;	Dirnberger	&	Jahanshahi,	2013),	and	an	early	diagnosis	of	PD-MCI	is	crucial,	for	its	association	to	progression	into	PDD.	The	cognitive	screening	tools,	often	used	in	a	clinical	routine,	are	short	and	can	be	easily	applied,	contrary	to	more	advanced	neuropsychological	assessments.	For	study	purposes	the	Mini-Mental	State	Examination	is	often	a	go-to	screening	tool,	even	though	its	sensitivity	has	been	proven	to	be	lower	than	that	 of	 the	 MoCA,	 especially	 for	 detecting	 early	 mild	 cognitive	 impairments	 (Nazem	 et	 al.,	 2009).	Research	supports	the	assumption	that	choosing	MoCA	as	a	global	screening	tool	is	preferable	to	MMSE	(Dalrymple-Alford	et	al.,	2010;	Hoops	et	al.,	2009).	As	the	MoCA	has	been	designed	for	AD	patients,	a	new	 scoring	 algorithm,	 which	 should	 improve	 the	 diagnostic	 accuracy	 of	 PD-MCI	 was	 developed	(Fengler	 et	 al.,	 2016).	 The	 results	 showed,	 that	 through	 the	 transformed	 scoring	 algorithm,	 the	sensitivity	of	MoCA	increases,	without	losing	the	specificity	or	jeopardizing	sensitivity	for	type	I	and	II	
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errors.	As	PDD	patients	were	included	into	the	study,	the	results	might	be	biased	by	these	cases	and	the	cut-off	may	be	more	applicable	to	the	later	stages	of	PD-MCI.	Excluding	PDD	patients	would	allow	one	to	valuate	 if	 the	novel	 scoring	algorithm	would	also	discriminate	between	early	PD-MCI	and	PD-NC	patients.				
Cognitive	Aspects	of	Urinary	Dysfunction	in	Parkinson’s	Disease		The	prevalence	of	urinary	symptoms	is	common	in	PD	and	other	neurodegenerative	diseases	and	has	been	associated	with	dementia,	as	incidence	of	urinary	problems	is	highest	among	demented	patients	(Chiang	et	al.,	2015;	Kessler,	2008;	Ransmayr	et	al.,	2008).			The	prefrontal	cortex,	which	also	has	projections	to	anterior	cingulate	cortex	(ACC)	or	insula,	plays	a	role	in	the	sensation	of	bladder	fullness	(Kitta	et	al.,	2016)	and	has	been	observed	during	bladder	filling	(Kitta	et	al.,	2015).	The	basal-ganglia	circuit	suppresses	micturition	reflex	in	healthy	adults	(Sakakibara	et	 al.,	 2010;	Hattori	 et	 al.,	 1992).	 In	 PD,	 this	 circuit	 seems	 to	 be	 impaired	 causing	 range	 of	 bladder	problems	(Bonnet	et	al.,	1997;	Seki	et	al.,	2001).		The	activity	and	structural	connectivity	in	the	frontal	lobe,	ACC,	anterior	cingulate	gyrus	(Yuan	&	Raz,	2014)	 as	 well	 as	 the	 cortico-basal	 ganglia	 loops	 (Graybiel,	 2000)	 has	 been	 attributed	 to	 both	 the	executive	functions	and	urinary	control.	Moreover,	the	direct	and	the	indirect	pathways	between	the	basal	ganglia	and	the	frontal	cortex	have	been	attributed	to	the	response	selection,	as	well	as	initiation	of	action	under	competition	or	conflict	(MacDonald	&	Byblow,	2015).	The	indirect	pathway	through	the	subthalamic	nucleus	inhibit	the	inappropriate,	or	no	longer	required	responses,	which	allows	one	to	execute	(select	and	initiate)	an	appropriate	response	through	the	direct	pathway	(Middleton	&	Strick,	2000;	Redgrave,	Prescott,	&	Gurney,	1999).	In	PD,	as	a	consequence	of	neurodegenerative	processes,	the	 pre-supplementary	 motor	 area	 becomes	 underactivated,	 with	 simultaneous	 over	 activity	 of	subthalamic	nucleus,	which	causes	deficits	in	inhibitory	control	(Beste,	Willemssen,	Saft,	&	Falkenstein,	2010;	Gauggel,	Rieger,	&	Feghoff,	2004).			During	 the	 course	 of	 the	 disease,	 the	 neurodegenerative	 processes	 influence	 autonomic,	 limbic	 and	somatomotor	systems	(Braak	et	al.,	2004),	impairing	pathways	involved	not	only	in	micturition	reflex,	but	also	in	cognitive	functions.			Due	to	the	fact	that	both	urinary	symptoms	and	cognitive	impairment	are	of	a	high	prevalence,	more	likely	to	appear	in	late	stages	of	the	disease	and	have	a	common	neurophysiological	pathway	(Fowler,	1999;	 Fowler	 et	 al.,	 2008;	 Fowler	 &	 Griffiths,	 2010),	 it	 is	 important	 to	 investigate	 the	 connection	between	 these	 two	phenomena	 in	 order	 to	 evaluate	 if	 there	 is	 a	 causal	 link	between	 cognition	 and	
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urinary	symptoms.	This	connection,	or	even	causal	relationship,	has	only	been	sparsely	investigated	in	PD	and,	therefore,	is	the	main	research	focus	of	this	doctoral	thesis.			
Publications	and	Scientific	Research	Question		The	main	goal	of	this	PhD	thesis	was	to	establish	a	detailed	clinical	characterization	of	PD-UU	(with	or	without	incontinence)	and	to	identify	cognitive	mechanisms	associated	with	UU	in	a	subgroup	of	PD	patients.	 The	 thesis	 aimed	 to	 evaluate	 the	 question	 whether	 it	 is	 possible	 to	 characterize	 a	subpopulation	of	PD	patients	whose	UU	is	primarily	influenced	by	cognitive	control	mechanisms.	This	subgroup	might	benefit	from	more	cognitive-driven	intervention	of	UU,	as	it	would	be	helpful	if	a	certain	clinical	profile	associated	to	potential	cognitive-driven	UU	could	be	identified.	In	the	second	part,	we	validated	a	 sensitive,	 economic	 test	battery-	MoCA,	which	 is	often	used	 in	a	 clinical	 interview,	 even	though	the	commonly	used	cut-offs	were	validated	among	Alzheimer’s	Disease	patients.	We	aimed	to	establish	 better	 diagnostic	 accuracy	 for	 PD-MCI,	 in	 order	 to	 improve	 the	 diagnostic	 value	 of	 this	commonly	used	screening	test.	
	
Research	Question	1	/	Publication	1:		In	this	explorative	study,	the	possible	link	between	cognition,	especially	in	frontal	lobe	functions,	PD-UU	and	other	non-motor	aspects	was	investigated.	For	this	purpose,	the	analysis	was	carried	out	within	a	 more	 heterogenous	 group	 of	 PD	 patients.	 The	 data	 was	 collected	 within	 the	 frame	 of	 the	“Verlaufsstudie	zur	Charakterisierung	kognitiver	Störungen	bei	Parkinson	Patienten”	study,	designed	to	 identify	 the	association	between	PD-UU,	cognition,	activity	of	daily	 living	 function	and	other	non-motor	 symptoms.	 The	 aim	 of	 this	 study	 was	 to	 examine	 if	 there	 is	 a	 correlation	 between	incidence/severity	 of	 urinary	 symptoms	 and	 cognition	 in	 a	 heterogenic	 PD	 group	 (all	 stages	 of	 the	disease)	in	order	to	address	the	following	research	gaps:			 a) 	What	is	the	prevalence	of	PD-UU	in	a	heterogenic	PD	sample?	b) Does	 the	 incidence	 of	 urinary	 symptoms	 in	 PD	 associate	 with	 other	 motor	 or	 non-motor	symptoms	of	PD?	c) Does	the	incidence	and/or	severity	of	PD-UU	have	any	association	with	cognition	in	PD?		
Research	Question	2	/	Publication	2:		The	aim	of	 the	 investigation	was	 to	examine	which	aspects	of	cognition	associate	with	PD-UU	more	deeply	in	order	to	identify	a	subgroup	of	patients	whose	UU	was	triggered	or	worsened	by	cognitive	impairment.	Therefore,	PD	patients	with	and	without	UU	were	compared,	while	controlling	for	physical	
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conditions	and	medication	interfering	with	bladder	function	or	cognition	in	a	large,	more	homogenous	non-demented	 PD	 sample	 with	 the	 aim	 of	 further	 investigating	 the	 following	 gaps	 in	 the	 current	research.		a) What	is	the	prevalence	of	PD-UU	in	the	ambulatory	treatment	setting?	b) Is	it	possible	to	identify	a	prototypical	PD	patient	whose	urinary	urgency	is	associated,	or	even	caused	by	cognitive	impairment?	c) Does	PD-UU	relate	to	the	instrumental	activity	of	daily	living	function	(iADL),	or	health	related	quality	of	life	(HRQoL)?		
Research	Question	3	/	Publication	3:			In	this	study,	we	validated	a	weighted	MoCA	scoring	algorithm	in	a	large,	non-demented	PD	population.	Our	aim	was	to	investigate	if	the	weighted	algorithm	would	have	better	diagnostic	accuracy	for	PD-MCI	and	would	show	a	stronger	correlation	to	results	of	more	specific	neuropsychological	assessments.		 a)		 Does	the	incidence	of	PD-MCI	change	when	using	weighted	MoCA	scoring?	b)		 Does	 the	 association	 with	 each	 cognitive	 domain	 (especially	 executive	 function)	 change	 in	weighted	MoCA	scoring?	c)		 What	is	the	optimal	cut-off	value	for	weighted	MoCA	in	order	to	reduce	type	II	errors?			
Results	und	Discussion			The	main	objective	of	 this	PhD	 thesis	was	 to	 investigate	 the	 link	between	urinary	urgency	 (with	or	without	incontinence)	and	cognitive	function	in	PD.	The	first	step	taken	was	to	explore	the	theoretical	and	methodological	background	of	this	association	in	an	unselected	cohort,	which	included	PDD	cases	and	concomitant	diseases.	Based	on	the	limitations	detected	in	this	step,	the	study	design	was	specified	and	the	 investigation	was	conducted	on	a	non-demented	PD	sample,	excluding	patients	who	receive	medication	 and/or	 suffer	 from	 concomitant	 diseases	 could	 potentially	 influence	 either	 cognition	 or	urinary	symptoms.		An	additional	 focus	of	 this	doctoral	 thesis	was	to	 find	a	way	to	 improve	early	diagnosis	of	cognitive	deterioration,	which	increases	the	risk	for	PDD.	Thus,	a	new	scoring	algorithm	developed	to	improve	diagnostic	accuracy	when	using	the	MoCA,	a	commonly	used	cognitive	test	battery,	to	detect	PD-MCI	was	evaluated	in	a	non-demented	PD	population.		Idiopathic	PD	has	been	 long	 considered	a	movement	disorder,	 caused	by	degenerative	processes	of	substantia	 nigra.	 The	 high	 prevalence	 of	 non-motor	 symptoms	 has	 recently	 been	 recognized	 and	become	a	focus	of	scientific	research	(Berganzo	et	al.,	2016;	Marras	&	Chaudhuri,	2016;	Pfeiffer,	2016;	
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Sauerbier,	Jenner,	Todorova,	&	Chaudhuri,	2016).	Non-motor	symptoms	create	a	great	challenge,		for	clinicians	as	well	as	for	patients	and	their	caregivers,	appearing	even	before	motor	symptoms	do,	and	in	some	cases	dominating	the	clinical	phenotype	(Chaudhuri,	Odin,	Antonini,	&	Martinez-Martin,	2011).	The	scientific	importance	of	investigating	the	relationship	between	PD-UU	and	cognitive	function	arises	from	the	high	prevalence	among	PD	patients,	strong	negative	impact	on	everyday	life	and	predictive	value	for	a	faster	disease	progression	(Bartoli,	Aguzzi,	&	Tarricone,	2010;	Fereshtehnejad	et	al.,	2015).	Bladder	symptoms	can	be	found	in	28%-71%	of	PD	patients,	and	are,	therefore,	significantly	higher	than	in	 healthy	 elderlies.	Moreover,	 urinary	 symptoms	 are	 highly	 prevalent	 in	 other	 forms	 of	 dementia,	suggesting	an	association	with	the	severity	of	cognitive	impairment	(Chiang	et	al.,	2015;	Ransmayr	et	al.,	2008;	Tateno	et	al.,	2015).			
Association	of	Cognition	and	PD-UU		The	 association	 between	 urinary	 dysfunction	 and	 neuropsychological	 test	 performance	 in	 PD	 was	initially	investigated	in	a	broad,	unselected	PD	cohort,	which	included	patients	of	all	cognitive	states:	PD	with	normal	cognition	(PD-NC),	PD-MCI	and	PDD.	All	concomitant	diseases,	except	for	depression,	as	 it	 is	known	 to	worsen	cognitive	performance	 (Bhardwaj,	Wilkinson,	Srivastava,	&	Sharma,	2010)	were	taken	into	consideration.	The	association	of	cognition	was	analysed	between	PD-UU	and	PD-NUU	patients,	 followed	 by	 a	 comparison	within:	 PD-UU	 patients	 without	 urological	 treatment	 vs	 PD-UU	patients	who	had	received	urological	treatment.	Patients	who	had	received	urological	treatment	were	considered	 to	 experience	more	 severe	 bladder	 symptoms	 than	patients	who	 had	not	 received	 such	treatment.		This	 explorative	 study	 showed	 that	 PD-UU	 patients	 suffered	 from	 a	 greater	 level	 of	 cognitive	impairment	 than	 PD-NUU,	 measured	 by	 the	 PANDA	 (Parkinson	 Neuropsychometric	 Dementia	Assessment-Test).	 This	 effect	 remained	 significant	 in	 a	 PD-UU	within	 comparison.	 Additionally,	 we	assessed	a	comprehensive	neuropsychological	test	battery	(see	Publication	1)	to	the	PANDA	in	order	to	evaluate	cognitive	domains,	 important	 for	diagnosing	PD-MCI,	or	PDD:	executive	 functions,	working	memory,	 attention,	memory,	 language	 and	 visuo-construction	 (Litvan	 et	 al.,	 2012;	Martinez-Martin,	Falup-Pecurariu,	 et	 al.,	 2011).	 Among	 these	 domains,	 PD-UU	 patients	 performed	 worse	 on	 visuo-construction	 tests	 than	PD-NUU	patients.	Here	as	well,	 the	 results	were	able	 to	be	 replicated	 in	 the	subgroup	comparison.			Hence,	not	only	presence,	but	also	severity	of	PD-UU	was	associated	to	cognitive	impairment,	especially	visuo-construction,	in	the	sample	of	PD	patients.	The	findings	of	this	study	confirm	previous	studies	that	reported	 high	 prevalence	 of	 PD-UU	 in	 late	 stages	 of	 PD	 (Winge	 &	 Nielsen,	 2012).	 Moreover,	 more	advanced	 cognitive	 decline,	 represented	 by	 visuo-constructive	 deteriorations	 (Williams-Gray	 et	 al.,	2009),	was	found	to	be	associated	with	PD-UU.	Visual	perception	deficits	are	a	frequent	manifestation	
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in	 PD	 (Aarsland,	 2016).	 Neuroimaging	 studies	 taking	 into	 account	 activation	 of	 cortical	 areas	 and	networks	involved	in	visual	perception	processes	showed	reduced	activation	of	basal	ganglia	networks	and	 a	 greater-	 compensatory	 activation	 in	 prefrontal	 cortex	 (Caproni	 et	 al.,	 2014).	 The	neurodegeneration	of	the	part	of	the	basal	ganglia	network	that	is	involved	in	executive	processes	in	PD,	has	a	direct	influence	on	visuo-constructive	processes	(Umarova	et	al.,	2010).			Urgency,	with	 or	without	 incontinence	 can	 result	 from	many	 origins,	 such	 as	 detrusor	 overactivity,	cognitive	and	behavioural	problems,	urological	causes	or	aging	processes	(Panicker,	Fowler,	&	Kessler,	2015).	The	high	prevalence	of	bladder	dysfunction	in	other	forms	of	dementia	and	a	close	link	between	other	 autonomic	 problems	 and	 cognitive	 impairment	 strengthens	 the	 hypothesis	 that	 these	 two	neurodegenerative	processes	 can	 influence	each	other	during	 the	 course	of	 the	disease	 (Idiaquez	&	Roman,	 2011).	 Autonomic	 functions,	 in	 general,	 have	 been	 investigated	 in	 the	 context	 of	 previous	neuroimaging	or	neuropsychological	studies	in	order	to	improve	the	understanding	of	the	co-existence	of	autonomic	failure	and	cognitive	deterioration	(Heims	et	al.,	2006).	Subtle	cognitive	 impairment	 is	almost	universally	distributed	among	PD	patients	and	can	even	appear	in	early	stages	of	the	disease	(Broeders	et	al.,	2013;	Muslimovic,	Post,	Speelman,	&	Schmand,	2005).	The	impairment	relates	to	the	front-striatal	 loop,	 with	 projections	 to	 the	 frontal	 cortex,	 related	 to	 executive	 dysfunction,	 which	involves	 planning,	 goal	 oriented	 behaviour	 or	 inhibition	 of	 unwanted,	 or	 unneeded	 behaviour	(Dirnberger	 &	 Jahanshahi,	 2013;	 Dubois	 &	 Pillon,	 1997;	 Yuan	 &	 Raz,	 2014).	 Yet,	 the	 link	 between	cognition	and	bladder	symptoms	has	been	sparsely	investigated	among	PD	patients	(Heims	et	al.,	2006;	Pilleri,	Koutsikos,	&	Antonini,	2013).	Urinary	problems	are	highly	prevalent	in	dementia;	however,	the	timing	of	its	occurrence	varies	between	neurological	disorders	(Aubin	et	al.,	2015;	Birder	et	al.,	2010;	de	Groat	et	al.,	2015;	Ogawa	et	al.,	2017).	Neuroimaging	studies	suggest	at	least	a	neurophysiological	relationship	between	PD-UU	and	cognition	(Fowler,	1999;	Fowler	et	al.,	2008;	Griffiths	&	Fowler,	2013),	proposing	that	the	integrated	cortical	neurodegenerative	process	might	influence,	or	be	dependent	on	bladder	dysfunction,	and	the	prevalence	of	urinary	symptoms.	The	inhibitory	effect	of	basal	ganglia	on	micturition	 is	 disrupted	 in	 PD	 patients	 (Kitta	 et	 al.,	 2016;	 Kitta	 et	 al.,	 2006;	 Kitta	 et	 al.,	 2015).	Furthermore,	it	has	been	shown	that	the	frontal	cortex	plays	an	important	role	in	regulating	micturition	(Griffiths	 &	 Fowler,	 2013;	 Panicker	 et	 al.,	 2015),	 being	 a	 region	 with	 many	 direct	 and	 indirect	connections	with	areas	associated	with	autonomic	control,	and	playing	an	 inhibitory	role	 (Fowler	&	Griffiths,	2010;	Yamamoto	et	al.,	2010).			During	the	course	of	the	disease,	impairment	of	executive	functions	occurs	in	approximately	30%	of	PD	patients	(Bronnick	et	al.,	2006;	C.	C.	 Janvin	et	al.,	2006;	Puente,	Cohen,	Aita,	&	Brandt,	2016).	Visuo-constructive	impairment,	which	was	found	to	be	associated	to	presence	and	severity	of	PD-UU,	appears	later	in	the	disease	course	and	has	been	connected	to	accelerated	cognitive	decline	and	PDD	(Williams-Gray	et	al.,	2009).	However,	visuo-construction	is	a	very	complex	cognitive	function.	To	solve	a	visuo-construction	 task,	 subjects	 often	 use	 top-down	 and	 bottom-up	 systems	 that	 also	 refer	 to	 executive	aspects,	such	as	inhibiting	irrelevant	information,	planning	and	unifying	ambiguous	stimuli	(Kastner	&	Ungerleider,	2000;	Miller	&	Cohen,	2001).	It	 is	possible,	that	executive	impairment	influenced	visuo-
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constructive	 performance,	 however,	 this	 finding	 needed	 to	 be	 revaluated	 in	 a	 selected	 group	 of	 PD	patients.	To	investigate	the	association	of	cognition	and	PD-UU	more	deeply,	we	took	the	limitations	of	the	first	study	into	account	and	designed	our	second	study,	excluding	patients	with	either	PDD,	or	whose	medication/concomitant	disease	could	influence	either	cognition	or	urinary	function.	To	assess	a	global	cognitive	state,	the	MoCA,	which	is	known	to	be	a	sensitive	tool	for	early	cognitive	changes	in	PD	(Hoops	et	 al.,	 2009)	 was	 chosen.	 Additionally,	 an	 extended	 neuropsychological	 assessment	 was	 performed	along	with	the	creation	of	test	clusters	for	every	cognitive	domain,	making	the	measurement	of	each	domain	more	robust	with	regard	to	reliability	bias.	To	reduce	the	psychometric	quality	bias,	a	mean	z-value	 for	 every	 cognitive	 domain	 was	 calculated,	 utilizing	 the	 cognitive	 subtests	 assigned	 to	 each	domain.	Only	the	mean	z-value	of	executive	function	distinguished	significantly	between	PD-UU	and	PD-NUU.	This	finding	confirmed	our	theoretical	hypothesis	of	a	prefrontal	cognitive	involvement,	expressed	by	executive	impairment	in	PD-UU.	This	finding	is	also	in	line	with	other	studies,	which	have	found	a	connection	between	inhibitory	function	and	urinary	problems	in	other	neurological	disorders	such	as	vascular	dementia,	leukaraiosis,	or	Alzheimer’s	disease	(Del-Ser,	Munoz,	&	Hachinski,	1996;	Drachman,	O'Donnell,	Lew,	&	Swearer,	1990;	Haruta	et	al.,	2013),	however,	contradictory	to	a	longitudinal	study	(Picillo	et	al.,	2017).			To	answer	 the	question	of	why	 the	 findings	of	 this	 thesis	differ	 from	previous	 finding	 (Picillo	et	al.,	2017),	the	chosen	assessment	needs	to	be	taken	in	to	consideration.	In	their	study,	Picillo	et	al.	observed	no	 differences	 in	 the	 cognitive	 assessment	 while	 using	 the	 Minimental-State	 Examination	 (MMSE)	(Picillo	 et	 al.,	 2017).	 The	 MMSE	 was	 originally	 designed	 to	 assess	 cognitive	 impairment	 in	 AD,	nevertheless	has	been	used	as	a	screening	tool	for	PDD.	Values	below	26	points	would	indicate	possible	dementia	in	PD	(Hoops	et	al.,	2009).	However,	it	has	been	shown	that	MMSE	cannot	be	used	as	a	reliable	screening	 tool	 for	 PD	 cognitive	 deteriorations	 especially	 in	 early	 stages	 of	 cognitive	 deterioration	(Burdick	et	al.,	2014),	as	it	has	a	poor	sensitivity	for	detecting	cognitive	impairment,	including	PD-MCI	(Nazem	 et	 al.,	 2009).	 Moreover,	 a	 variety	 of	 cognitive	 problems,	 including	 PDD	 could	 have	 been	observed	even	in	patients	who	performed	above	a	proposed	cut-off	(Hoops	et	al.,	2009;	Zadikoff	et	al.,	2008).	In	order	to	improve	the	diagnosis	of	cognitive	deterioration	that	can	contribute	to	PD-UU,	a	more	sensitive	screening	tool	should	be	applied	in	daily	clinical	routine.	The	MoCA	screening	assessment	has	been	shown	to	be	more	reliable	to	differentiate	between	cognitive	states	in	PD,	and	covers	a	broad	range	of	cognitive	domains	(Dalrymple-Alford	et	al.,	2010;	Wood	et	al.,	2016),	which	will	be	discussed	in	the	last	study	included	into	this	thesis.			
Prevalence	and	Demographics	of	PD-UU	
 This	 thesis	 confirmed	 previous	 findings	 that	 urinary	 symptoms	 are	 highly	 prevalent	 in	 the	 PD	population,	as	over	50%	of	the	study	participants	reported	at	least	mild	urinary	symptoms	(Araki	et	al.,	2000;	Ogawa	et	al.,	2017).	For	the	first,	exploratory	study	94	PD	patients	were	included,	out	of	which	
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55.3%	 reported	 urinary	 problems.	 PD-UU	patients	were	more	 frequently	men,	 of	 higher	 education.	When	 comparing	 PD-UU	 patients	 who	 received	 urological	 treatment	 with	 PD-UU	 patients	 without	treatment,	we	found	that	higher	educated	men	were	more	probable	to	receive	medical	treatment	for	PD-UU.	However,	this	could	be	a	potential	inclusion	bias,	as	no	correlation	between	PD-UU	and	age	of	onset,	age	of	diagnosis	was	evident	in	the	second	study.	A	possible	explanation	for	this	could	be	that	within	this	age	range	men	tend	to	be	more	highly	educated	than	women.	Consequently,	men	may	seek	medical	 attention	more	 often	 or	 be	 keener	 on	 supporting	 scientific	 research.	Misconceptions	 about	urinary	problems	should	also	be	taken	into	account,	as	patients	often	assume	it	to	be	related	to	the	aging	process,	rather	than	PD	itself	(Moriarty	et	al.,	2016).			In	the	PD-UU	subgroup,	19.2%	were	diagnosed	with	PDD,	contrary	to	PD-NUD	patients,	where	PDD	was	only	detected	in	7.1%	of	patients.	This	finding	was	in	line	with	previous	findings,	showing	that	urinary	problems	 are	 more	 prevalent	 in	 dementia,	 based	 on	 community-dwelling	 and	 institutional	 studies	(Ouslander,	Palmer,	Rovner,	&	German,	1993;	Palmer,	German,	&	Ouslander,	1991).	Previous	research	has	revealed,	that	incontinence	episode	were	present	in	over	75%	of	demented	patients,	compared	to	only	5%	of	the	general	population	of	elderly	individuals	(A.	R.	Herzog	&	Fultz,	1990).	This	important	finding	strengthened	the	hypothesis	of	an	association	between	PD-UU	and	cognitive	impairment.		The	 link	 between	 dementia	 and	 urinary	 urgency,	 as	 well	 as	 the	 comorbidity	 of	 degenerative	 and	vascular	pathologies	has	been	reported	previously	(Campbell,	Reinken,	&	McCosh,	1985;	Nakanishi	et	al.,	1997;	Skelly	&	Flint,	1995)	.	However,	even	though	the	general	correlation	of	cognitive	worsening	and	 prevalence	 of	 bladder	 symptoms	was	 assumed	 (Marras	 &	 Chaudhuri,	 2016;	 Postuma,	 Gagnon,	Pelletier,	&	Montplaisir,	2013),	it	was	important	to	investigate	to	what	extent	this	correlation	is	valid.	Furthermore,	a	causative	relationship	of	these	symptoms	was	not	clear.	Of	particular	importance	is	that	urinary	 urgency	must	 not	 be	 accompanied	 by	 cognitive	 impairment	 or	 dementia	 (Sakakibara	 et	 al.,	2005),	which	implies	that	the	association	between	these	two	non-motor	symptoms	is	valid	for	a	subtype	of	PD	patients	and	cannot	be	generalized	to	the	whole	PD	population.				
Further	Symptoms	of	a	Prototypical	PD-UU	Patient	
 
Motor	Symptoms		It	 is	still	up	to	debate	whether	there	is	an	association	between	motor	progression	and	PD-UU.	Some	studies	have	concluded	that	urinary	dysfunction	can	be	associated	to	disease	severity	(Araki	et	al.,	2000;	Winge	&	Fowler,	2006)	or	motor	symptoms,	other	studies	have	failed	to	prove	this	association	(Campos-Sousa	et	al.,	2003;	Hobson,	Islam,	Roberts,	Adhiyman,	&	Meara,	2003).	In	the	research	of	this	thesis,	no	correlation	was	found	between	motor	impairment,	measured	by	the	Unified	Parkinson	Disease	Rating	scale	(UPDRS	III),	or	disease	severity,	measured	by	the	Hoehn	und	Yahr	(H&Y)	and	PD-UU.	This	finding	
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supports	 the	 hypothesis	 that	motor	 symptoms	 and	 PD-UU	might	 develop	 independently.	 However,	some	disproportion	of	the	distribution	of	the	H&Y	stages	was	observed.	In	the	second	study,	stage	2	was	overrepresented	as	well	among	PD-NUU	as	PD-UU.	As	patients	in	more	advanced	stages	of	the	disease	generally	might	be	less	willing	to	participate	in	scientific	studies,	whereas	patients	in	earlier	stages	may	simply	 not	 have	 time	 for	 study	 participation	 because	 they	 are	 still	 well	 integrated	 in	 social	 and	professional	 life,	 we	 cannot	 exclude	 the	 possible	 bias	 of	 the	 results.	 Considering	 these	 issues,	 the	possibility	of	type	1	error	is	higher	than	anticipated.	It	is	possible,	that	motor	impairment	contributes	indirectly	to	PD-UU,	however,	our	data	cannot	support	this	evidence.		The	second	study	revealed,	that	PD-UU	had	in	average	a	longer	disease	duration	than	PD-NUU	patients.	This	effect	was	not	supported	by	the	discriminative	analysis,	which	did	not	assign	disease	duration	to	the	PD-UU	group.	It	confirmed	our	previous	finding	that	disease	duration	per	se	does	not	contribute	independently	to	subtyping	the	PD-UU	subgroup.	In	the	literature,	reports	considering	disease	duration	and	PD-UU	are	heterogeneous.	Some	studies	show	that	PD-UU	can	be	detected	at	median	12	years	after	PD	diagnosis	(Wenning	et	al.,	1999),	whereas	others	report	an	early	onset	(Uchiyama	et	al.,	2011).	These	conflicting	outcomes	emphasize	the	importance	of	differentiating	between	age-related	and	PD-related	bladder	problems	as	an	important	confounding	variable	(Zhang	&	Zhang,	2015).	So	far,	two	prospective	studies	have	investigated,	whether	the	frequency	of	PD-UU	increases	during	the	course	of	PD	(Ou	et	al.,	2016;	 Picillo	 et	 al.,	 2017).	 Both	 studies	 confirm	 an	 increasing	 tendency	 of	 a	 prevalence	 of	 bladder	symptoms,	 over	 time.	 Additionally,	 another	 study	 determined	 that	 in	 advanced	 PD,	 prevalence	 and	severity	of	PD-UU	is	significantly	higher	than	in	moderate	PD	(Winge	&	Nielsen,	2012)	and	that	disease	severity	seems	to	influence	bladder	symptoms	significantly	(Campos-Sousa	et	al.,	2003).	These	results	support	the	hypothesis	that	urinary	dysfunction	caused	by	PD	is	a	specific	symptom	that	can	be	detected	in	 a	 specific	 subtype	 of	 heterogeneity	 of	 the	 disease,	 rather	 than	 a	 consequence	 of	 dopaminergic	degeneration	or	simply	aging	processes.			
Other	Non-Motor	and	Autonomic	Symptoms	
 James	 Parkinson	 did	 not	 describe	 PD	 as	 a	motor	 disorder	 exclusively	 (Horowski,	 Horowski,	 Vogel,	Poewe,	 &	 Kielhorn,	 1995).	 He	 also	 noted	 the	 prevalence	 of	 non-motor	 symptoms	 such	 as	 sleep	disturbance,	 constipation	 or	 urinary	 incontinence.	 However,	 non-motor	 symptoms	 have	 not	 been	focused	on	for	many	years,	even	though	almost	100%	of	all	PD	patients	report	at	least	one	non-motor	symptom	(Pfeiffer,	2016).	The	clinical	spectrum	of	non-motor	symptoms	in	PD	is	a	consequence	of	a	widespread	 neuronal	 pathology	 of	 this	 disorder.	 Patients	 with	 PD	 experience	 a	 combination	 of	dysautonomic	symptoms,	cognitive	impairment	and	fluctuations	in	non-motor	symptoms,	such	as	pain,	sweating	or	 fatigue	(Witjas	et	al.,	2002).	Even	though	the	neurological	pathway	of	motor-;	and	non-motor	 symptoms	 seems	 to	 be	 of	 common	 origin,	 the	 neuropathology	 of	 PD-UU	 has	 not	 been	 fully	explained	yet.	It	has	been	shown,	that	PD-UU	patients	suffer	from	more	frequent	and	severe	non-motor	symptoms	than	PD	patients	with	no	bladder	dysfunction	(Picillo	et	al.,	2017),	which	we	were	able	to	
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confirm	in	the	second	study	of	this	thesis.	Furthermore,	evidence	shows,	that	non-motor	symptoms	tend	to	aggregate,	and	bi-influence	each	other,	resulting	in	a	considerable	negative	impact	on	patients	and	their	caregivers	(Jain,	2011;	Sauerbier	et	al.,	2016).			Another	important	factor	influencing	PD-UU	is	the	affective	disorder,	which	is	common	in	PD	and	may	occur	in	every	stage	of	the	disease	(Reijnders,	Ehrt,	Weber,	Aarsland,	&	Leentjens,	2008).	Even	though	depression	 is	attributed	to	the	serotonin	deficiency,	 levodopa	medication	has	been	shown	to	reduce	depressive	symptoms	(Chaudhuri,	Healy,	et	al.,	2006),	which	indicates	neuropathological	connection.	Bladder	dysfunction	is	common	in	both,	depression	and	in	PD,	but	is	more	prevalent	in	PD	patients	than	those	 suffering	 from	depression	 (Sakakibara	 et	 al.,	 2013).	 The	 affective	 disorder	 contributes	 to	 the	cognitive	worsening,	influencing	performance	in	executive	tasks	(Marvel	&	Paradiso,	2004),	which	was	also	impaired	in	PD-UU	patients	in	the	second	study	of	this	thesis.	Moreover,	findings	of	neuroimaging	studies	confirm	that	cognitive	impairment	in	depression	is	linked	to	disturbances	in	the	activity	of	the	prefrontal	 cortex,	 ACC	 and	 hippocampus	 (Degl'Innocenti,	 Agren,	 Sjogren,	 Zachrisson,	 &	 Backman,	1999),	 cortical	 structures	 also	 impaired	 in	 PD-UU	 patients	 (Griffiths	 &	 Fowler,	 2013).	 Therefore,	depression	was	 assumed	 as	 a	 possible	 confounder	 and	has	 been	 examined	 in	 all	 of	 our	 studies.	No	differences	were	detected	 for	 the	PD-UU	and	PD-NUU	groups,	which	strengthens	 the	 findings	of	 the	connection	between	cognitive	impairment	and	PD-UU.			
PD-UU	and	Quality	of	Life	
 The	 influence	of	urinary	dysfunction	on	 the	daily	 life	of	PD	patients	 is	very	 complex.	As	 introduced	earlier,	bladder	dysfunction	can	occur	throughout	the	course	of	the	disease,	but	is	more	prevalent	in	late	stages	among	PDD	patients	and	can	impair	patients’	quality	of	life	to	a	greater	extent	than	motor	deteriorations	do	(Pfeiffer,	2016).	Studies	suggest	that	bladder	dysfunction	is	perceived	by	patients	as	more	 bothersome	 than	 other	 non-motor	 symptoms,	 which	 results	 in	 a	 greater	 negative	 impact	 on	quality	of	life	(Yeo,	Singh,	Gundeti,	Barua,	&	Masood,	2012).			In	the	first	study,	iADL	was	found	to	be	more	impaired	in	PD-UU,	however	this	effect	disappeared	when	different	severity	levels	of	PD-UU	were	compared.		This	finding	indicates	that	in	PD-UU,	prevalence	but	not	the	severity	of	urinary	symptoms	contributes	to	the	impairment	of	iADL.	To	investigate	this	issue,	a	post-hoc	analysis	was	performed.	It	was	shown,	that	the	worsening	of	iADL	function	correlated	to	the	cognitive	worsening,	which	was	observed	in	the	PD-UU	subgroup.	Previous	studies	have	shown	that	PD-MCI,	which	often	precedes	PDD,	is	accompanied	by	the	worsening	in	iADL	(Leroi,	McDonald,	Pantula,	&	Harbishettar,	2012).			As	PD-UU	patients	in	the	first	study	experienced	lower	iADL,	it	can	be	assumed	that	PD-UU	contributes	to	 the	progression	of	 the	disease	and	conversion	to	PDD.	This	 finding	could	not	be	replicated	 in	 the	
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second	study,	however,	changes	in	the	HRQoL	related	to	Stigma	were	assigned	as	a	symptom	of	the	PD-UU	group.	The	surprising	part	of	the	result	was,	that	Stigma	related	to	HRQoL	was	lower	among	PD-UU	patients	 than	PD-NUU.	Evidence	shows,	 that	stigma,	arising	 from	health-related	symptoms	 is	higher	among	PD	patients	 than	HI,	 as	 it	 can	 lead	 to	 social	withdrawal	 (Hermanns,	 2013;	Ma,	 Saint-Hilaire,	Thomas,	 &	 Tickle-Degnen,	 2016).	 It	 is	 also	 known	 that	 PD	 patients	 have	 a	 reduced	 interoceptive	sensitivity,	leading	to	the	reduced	acknowledging	of	physiological	abnormalities,	when	compared	to	the	healthy	population	of	the	same	age	(Ricciardi	et	al.,	2016).	The	reversed	Stigma	direction	in	our	study	can	imply	that	PD-UU	patients	do	not	fully	perceive	the	urinary	urgency,	or	deny	the	symptoms.	It	is	important	 to	mention,	 that	 interoceptive	perception	 is	modulated	by	the	ACC,	which	also	modulates	performance	in	executive	tasks	(Fowler	&	Griffiths,	2010).	The	results	of	this	study	may	indicate	that	a	lower	stigma	burden	is	a	secondary	outcome	alongside	with	executive	impairment	among	our	PD-UU	group.	To	gain	further	insight	into	this	particular	connection,	further	studies	are	required.			
The	Validation	of	a	Weighted	MoCA	Scoring	in	Non-Demented	PD	Patients	
 Deficits	 in	 executive	 functions	are	 common	 in	PD	 (Dirnberger	&	 Jahanshahi,	 2013)	 and	 incorporate	problems	in	planning,	cognitive	flexibility,	inhibition,	generating	strategies,	and	abstract	thinking	(Stuss	&	Alexander,	2000).	Even	though,	cognitive	impairment	has	a	vast	impact	on	the	daily	life	of	PD	patients,	it	frequently	stays	underdiagnosed	in	the	early	stages	of	the	disease.	Very	often	short	screening	tests	are	 the	 only	 ones	 used	 to	 detect	 cognitive	 deteriorations,	 delivering	 many	 false	 positive	 and	 false	negative	results	(Fengler	et	al.,	2016).	Prevalence	studies	report	that	during	the	course	of	the	disease,	up	to	80%	of	PD	patients	are	at	risk	for	developing	PDD	(Aarsland,	2016),	and	up	to	60%	will	develop	bladder	dysfunction	(Araki	et	al.,	2000).	Based	on	these	findings,	there	is	clearly	a	great	need	for	a	valid	diagnostic	 tool	 to	 identify	 those	 patients	 at	 risk	 for	 cognitive	 impairment	 early	 on.	 Therefore,	 it	 is	important	 to	 focus	 on	 neuropsychological	 assessments	 that	 could	 be	 integrated	 into	 the	 everyday	clinical	routine	and	would	be	highly	sensitive	to	initial	cognitive	deteriorations	in	PD.			In	general,	the	PD-MCI	concept	has	a	relatively	low	specificity,	as	there	is	no	consensus	about	which	and	how	many	cognitive	tests	are	needed	for	cognitive	profiling.	For	example,	the	diagnostic	criteria	of	the	Movement	 Disorder	 Task	 Force	 guidelines	 operate	 on	 dichotomous	 criteria	 of	 inclusion/	 exclusion	(Wood	et	al.,	2016)	and	the	cut-offs	are	often	derived	from	the	normative	data	(Aarsland	et	al.,	2003;	Foltynie	et	al.,	2004).	The	cut-off	for	PD-MCI,	is	therefore	defined	as	a	SD	-<1.5	of	normative	data	(Hoops	et	 al.,	 2009).	A	 very	 commonly	used	 test	 battery	 for	detecting	 cognitive	deteriorations	 is	 the	MoCA	(Nasreddine	et	al.,	2005),	originally	designed	for	detecting	cognitive	changes	in	AD.	The	main	critique	concerning	the	MoCA	is	that	the	scoring	system	does	not	consider	subtest	discriminant	power,	which	would	represent	the	cognitive	decline	in	PD	more	correctly,	with	a	higher	impact	on	executive	decline	(Fengler	et	al.,	2016).	As	a	result,	a	new	a	subtest-discriminant	algorithm	was	proposed	(Fengler	et	al.,	2016).	 This	 algorithm	 has	 been	 reported	 to	 be	 more	 sensitive	 for	 cognitive	 deterioration	 in	 a	 PD.	
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However,	 this	validation	study	 included	all	 the	 stages	of	 cognitive	 impairment,	which	made	 it	more	difficult	to	determine	whether	or	not	this	weighing	method	is	an	accurate	way	to	distinguish	between	PD-NC	and	PD-MCI,	or	if	the	findings	contribute	to	the	cognitive	impairment	related	to	PDD.	Therefore,	an	 evaluation	 of	 a	 weighted	 MoCA	 scoring	 algorithm	 was	 conducted	 in	 a	 large,	 non-demented	 PD	population	in	order	to	investigate	the	effect	on	the	accuracy	of	PD-MCI	diagnosis	and	the	potential	to	minimize	the	risk	of	false-negative	errors.			In	the	third	study,	the	PD-MCI	classification	was	defined	as	followed:	The	1	SD	cut-off	74	PD-NC	(36.6%)	and	128	(63.4%)	PD-MCI	patients,	 the	1.5	SD	cut-off	to	125	(61.9%)	PD-NC	and	77	(38.1%)	PD-MCI	patients,	and	the	2	SD	cut-off	to	162	(80.2%)	PD-NC	and	40	(19.2%)	PD-MCI	patients.	According	to	the	1,	1.5,	or	2	SD	cut-off,	93.8%,	93.5%,	and	95.0%	respectively,	of	all	PD-MCI	patients	were	classified	as	multi-domain	PD-MCI.		By	applying	a	2	SD	cut-off,	an	interesting	result	was	observed.	The	PD-NC	patients	scored	significantly	lower	than	in	non-weighted	MoCA,	which	let	us	assume	that	while	using	2	SD	cut-off	few	cases	of	an	early	PD-MCI	can	be	observed.	Whether	or	not	this	subgroup	of	patients	was	in	risk	of	progressing	to	PD-MCI	should	be	investigated	in	a	 longitudinal	study,	however,	we	assume	that	this	cut-off	 is	more	sensitive	to	the	subgroup	of	PD	patients	who	will	experience	steeper	cognitive	decline.		As	expected,	the	PD-MCI	classification	was	highly	dependent	on	the	used	cut-off	as	well,	which	in	the	study	of	this	thesis	was	shown	to	be	most	accurate	at	1.5	SD;	27	points	(for	the	weighted	MoCA).	The	cut-off	in	this	study	was	higher	than	the	cut-off	proposed	by	the	original	work:	26	points	(original	MoCA)	(Nasreddine	et	al.,	2005).	As	 the	MoCA	and	the	proposed	cut-off	were	evaluated	on	AD	patients,	we	assume	 that	 they	are	not	appropriate	 for	PD	patients,	 and	 that	our	 cut-off	 represents	PD-MCI	more	accurate	than	the	original	MoCA	does.			An	interesting	novelty	was	that	only	the	2	SD	cut-off	showed	higher	specifity	and	sensitivity,	compared	to	original	MoCA	scoring.	We	found	this	result	surprising,	as	the	weighted	MoCA	prioritises	subtests	assigned	to	executive	function,	which	are	more	present	in	early	stages	of	PD.	Our	data,	however,	shows	that	the	weighted	MoCA	is	advantageous	when	detecting	cognitive	impairment	in	more	advanced	stages	of	PD,	showing	a	higher	sensitivity	to	visuo-cognitive	deteriorations,	which	are	known	to	be	predictive	for	PDD	(Williams-Gray	et	al.,	2009).	A	possible	explanation	for	this	finding	is	that	the	weighted	MoCA	identifies	PD	patients	at	risk	of	developing	PDD	when	applying	a	2	SD	cut-off.	Nevertheless,	longitudinal	studies	are	needed	to	confirm	this	assumption.			Regarding	the	sensitivity	and	specifity	of	the	cut-offs,	significant	higher	values	were	observed	than	in	the	original	MoCA	(sensitivity	70.0%	vs.	72.5%;	and	specificity	65.4%	vs.	79.0%).	The	results	of	this	study	differ	to	Fengler’s	study,	who	tested	the	weighted	algorithm,	in	a	more	heterogenic	PD	population,	without	excluding	depression	as	a	confounder	(sensitivity:	68.8%	vs	73.5%;	specifity:66.7%	vs	79%).	Our	 findings	 show	 an	 improvement	 of	 the	 specifity,	 which	 reduces	 the	 likelihood	 of	 false	 negative	
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results.	This	is	especially	important	in	clinical	practice,	as	screening	tests	are	often	the	only	tool	used	in	a	daily	routine.		In	general,	as	well	the	weighted	as	the	original	MoCA	were	able	to	differentiate	between	PD-NC	and	PD-MCI.	 However,	 PD-MCI	 patients	 scored	 lower	 in	 the	 weighted	 version	 compared	 to	 the	 original,	implicating	more	advanced	stage	of	PD-MCI.	With	regard	 to	cognitive	domains,	both	MoCA	versions	correlated	moderately	with	every	domain	and	did	not	differ	significantly.		In	conclusion,	the	results	of	this	study	showed	that	the	newly	weighted	MoCA	has	a	high	sensitivity	to	detect	a	group	of	PD-MCI	patients,	who	are	likely	to	be	in	a	later	stage	of	the	PD-MCI.	At	the	2	SD	cut-off,	the	 weighted	 MoCA	 seems	 to	 be	 more	 sensitive	 with	 regard	 to	 the	 detection	 of	 PD-NC	 patients,	potentially	 at	 risk	 of	 PD-MCI.	 Screening	 tools	 such	 as	 the	MoCA	 are	 indispensable	 for	 clinical	 daily	routine	as	they	are	economic	in	time,	easy	to	administer	and,	furthermore,	can	indicate	whether	it	is	necessary	to	evaluate	patients’	cognitive	status	more	precisely.			
Limitations	and	Considerations	for	Future	Studies		
	This	thesis	research	has	limitations.	First	of	all,	the	design	of	our	first	study	allowed	the	inclusion	of	PDD	patients.	Even	though,	we	found	an	association	between	cognitive	impairment	and	presence	as	well	as	severity	of	PD-UU,	we	did	not	observe	early	changes	in	cognition	or	bladder	symptoms,	but	rather	put	focus	on	late	disease	stages,	where	the	neurodegenerative	processes	are	highly	developed.	This	was	the	reason	why	 the	 visuo-construction	was	 the	 cognitive	 function	 that	 associated	 to	 PD-UU	 in	 the	 first	publication,	rather	than	any	other	function.	The	impairment	of	visuo-constructive	function	appears	late	in	the	course	of	the	disease	and	reflects	a	more	advanced	neurodegenerative	state,	indicating	increased	probability	 of	 progressing	 into	 PDD	 (Williams-Gray	 et	 al.,	 2009).	 However,	 even	 though	 PD-UU	 is	overrepresented	in	dementia	(Sakakibara,	Uchiyama,	Yamanishi,	&	Kishi,	2008),	these	symptoms	may	appear	early	in	the	disease,	or	even	precede	motor	symptoms	(Sakakibara,	Uchiyama,	Yamanishi,	Shirai,	&	Hattori,	2008;	Uchiyama	et	al.,	2003).	To	investigate	the	nature	of	the	relationship	between	cognition	and	PD-UU	further	studies,	preferably	of	a	longitudinal	design,	are	needed.	The	second	study	in	a	non-demented	PD	population	was	designed	with	the	limitations	of	the	first	study	in	mind.	An	association	between	 executive	 functions	 and	 PD-UU	 was	 detected	 at	 this	 time	 and	 the	 discriminant	 analysis	confirmed	 that	executive	 functions	contribute	 to	 the	prediction	of	PD-UU.	The	 results	of	 the	 second	study	showed	that	in	earlier	stages	of	PD	executive	functions	differentiate	between	PD-UU	and	PD-NUU.	The	chosen	assessments,	however,	did	not	specify	which	aspects	of	executive	functions	specifically	were	deteriorated.	Following	theoretical	background	of	neuroimaging	studies,	the	basal	ganglia	and	frontal	cortex	 influence	micturition	 in	 an	 inhibitory	matter	 (Fowler	 et	 al.,	 2008;	 Fowler	 &	 Griffiths,	 2010;	Griffiths	&	Fowler,	2013).	The	ability	to	inhibit	an	ongoing	reaction	has	been	assigned	to	the	executive	domain	(Aron,	Fletcher,	Bullmore,	Sahakian,	&	Robbins,	2003;	Aron	&	Poldrack,	2006).	Therefore,	the	
	 21 
assumption	can	be	made	that	PD-UU	patients	would	perform	worse	on	inhibitory	tasks	when	compared	to	PD-NUU	or	healthy	subjects.	This	aspect	 should	be	 investigated	 in	 future	studies.	A	 link	between	urinary	 urgency	 and	 inhibition	 has	 been	 shown	 for	 patients	with	 vascular	 dementia	 (Haruta	 et	 al.,	2013),	however,	it	has	not	yet	been	examined	for	PD-UU.		A	 further	 limitation	 of	 the	 first	 study	 was	 that	 comorbid	 illnesses	 that	 could	 influence	 bladder	symptoms,	such	as	diabetes	or	prostate	hyperplasia	were	not	excluded.	Previous	studies	have	shown	that	 men	 with	 mild	 to	 moderate	 PD	 report	 the	 same	 bladder	 symptoms	 as	 men	 with	 prostatic	enlargement	(Lemack,	Dewey,	Roehrborn,	O'Suilleabhain,	&	Zimmern,	2000).	Given	this	limitation,	the	results	 of	 the	 first	 study	may	not	 to	 be	 specific	 enough	 to	 single	 out	 the	bladder	 symptoms	 caused	primarily	by	PD.	Therefore,	the	second	study	included	only	a	specifically	selected	sample	of	PD	patients.	PDD	patients	as	well	as	any	subject	reporting	bladder	related	disease,	prior	to	PD	were	excluded.	In	addition,	comorbidities	such	as	diabetes,	other	age-related	causes	of	urinary	urgency	or	medication	that	would	interfere	either	with	urinary	tract	or	cognition	were	excluded	in	order	to	identify	a	subgroup	of	PD	patients	that	suffer	from	urinary	problems	caused	intrinsic	through	PD	itself.	The	results	showed	that	PD-UU	is	highly	prevalent	among	PD	patients	as	the	prevalence	rate	was	of	60.8%,	higher	than	in	previous	studies	(Martinez-Martin	et	al.,	2007).	As	mentioned	earlier,	 the	 focus	of	 this	 thesis	was	to	investigate	bladder	symptoms	that	can	be	contributed	to	the	neurogenic	origin,	therefore,	through	the	high	number	of	exclusions,	a	different	prevalence	rate	was	achieved.	In	none	of	our	studies	PD-UU	was	linked	to	age,	which	minimized	the	risk	of	including	symptoms	that	are	purely	age-related.		An	important	fact	was	that	groups	in	the	post-hoc	analysis	of	the	first	study	were	gender	biased,	as	only	highly	educated	men	received	urological	treatment.	The	obstacles	were	bypassed	by	setting	restrictions	in	the	statistical	analysis	of	the	first	study,	using	adjustments	in	a	regression	model	while	adding	gender	and	education	as	confounders.	However,	the	results	may	not	mirror	the	aspects	of	PD-UU	to	the	fullest	extent.			Another	 noteworthy	 critique	 is	 that	 bladder	 symptoms	 might	 be	 influenced	 by	 the	 parkinsonian	medication.	 Studies	 that	have	 investigated	 this	 topic	have	 revealed	 conflicting	 results.	 Some	studies	have	 reported	 that	 levodopa	 can	 improve	 the	 bladder	 symptoms	 (Aranda	&	 Cramer,	 1993),	 others	studies	 have	 found	 the	 opposite	 results	 (Uchiyama	 et	 al.,	 2003).	 Furthermore,	 voiding	 difficulty	 is	considered	to	be	reduced	during	the	“on”	state	(Araki	et	al.,	2000;	Hattori	et	al.,	1992;	Herzog	et	al.,	2006).	In	the	first	exploratory	study,	no	group	effect	according	to	LEDD	intake	was	detected.	The	second	study	 showed,	 that	 PD-UU	 was	 associated	 to	 a	 higher	 Levodopa	 intake,	 however,	 dopaminergic	antagonist	 equivalent	 dosage	did	not	 statistically	 differ	 between	 study	 groups.	 In	 the	 second	 study,	discriminant	analysis	showed	that	LEDD	should	not	be	interpreted	as	an	independent	predictor	for	PD-UU,	but	rather	represents	a	group	bias	that	was	specific	to	the	study	sample.		Anticholinergic	medication,	that	is	often	used	as	therapy	against	bladder	dysfunction,	has	been	shown	to	 worsen	 cognitive	 performance	 (Ehrt,	 Broich,	 Larsen,	 Ballard,	 &	 Aarsland,	 2010),	 which	 is	 why	
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patients	who	reported	anticholinergic	medication	intake	were	excluded	from	further	analysis	and	the	adverse	anticholinergic	effect	(ARS)	caused	by	other	medication,	as	suggested	by	Crispo	and	colleagues	(2016)	was	examined.	The	computed	ARS	 level	was	 the	same	 in	our	composed	PD-NUU	and	PD-UU	groups	 in	 both	 studies,	which	 eliminated	medication-induced	 bias	 and	 strengthened	 the	 results,	 as	cognitive	changes	among	PD-UU	were	disease-;	and	not	therapy-	driven.			A	urodynamic	examination	was	not	a	part	of	the	study,	however	the	assessment	of	urinary	problems	as	based	on	validated	self-reported	questionnaires.	When	using	self-reported	data,	one	must	assume	that	both,	false	negative	and	false	positive	cases	can	be	assessed.	The	questionnaires	however,	were	often	used	 in	 studies	 investigating	 urodynamic	 and	 are	 validated	 for	 assessing	 urinary	 problems,	 which	probably	eliminated	biasing	cases	of	UU.		The	next	issue	that	should	be	addressed	regards	the	quality	of	life.	The	results	of	the	first	study	show	that	 the	presence	and	not	 the	severity	of	PD-UU,	 reduces	 the	 iADL,	which	 is	 characteristic	 for	more	advanced	PD	population.	In	the	second	study,	HRQoL	related	stigma	was	significantly	lower	among	PD-UU	 patients,	 rather	 than	 PD-NUU.	 Studies	 show	 that	 PD	 patients	 experience	 lower	 interoceptive	sensitivity	when	compared	to	the	age	matched	healthy	population	(Ricciardi	et	al.,	2016),	which	could	explain	that	PD-UU	patients	achieved	lower	score	on	Stigma	related	to	HRQoL.	Moreover,	interoception	has	 been	 shown	 to	 be	 modulated	 by	 the	 anterior	 cingulate	 cortex,	 a	 cortical	 structure	 which	 also	modulates	executive	performance,	that	is	impaired	in	PD-UU	patients	(Kitta	et	al.,	2016).	Future	studies	are	required	to	gain	the	insight	into	to	what	extent	PD-UU	influences	perceived	quality	of	life.		An	obvious	limitation	is	the	cross-sectional	design	of	the	studies.	The	collected	data	should	be,	therefore,	interpreted	 as	 a	 snapshot	 and	 can	 be	 biased	 by	 the	 daily	 fluctuations	 of	 mood,	 tiredness	 etc.	 The	classification	of	symptoms	that	characterize	PD-UU	patients	should	be	addressed	in	a	longitudinal	study,	in	order	to	understand	the	possible	co-development	of	cognitive	functions	and	urinary	symptoms.			Concerning	 the	 third	 study,	 the	 differences	 in	 the	 data	 between	 our	 study	 and	 study	 conducted	 by	(Fengler	 et	 al.,	 2016;	Hoops	et	 al.,	 2009)	 could	have	 resulted	 from	 the	 fact	 that	 the	analysis	 for	 the	purpose	of	this	thesis	was	conducted	among	a	non-demented	PD	sample.	The	higher	cut-off	value	cannot	be	compared	entirely,	as	our	sample	lacked	PDD.		Moreover,	for	the	purpose	of	the	analysis	a	1,	1.5	and	2	SD	cut-offs	were	used.	The	original	study	by	Fengler	et	al.	used	a	cut-off	of	1.28	SD	for	the	CERAD	subtests,	as	suggested	in	the	manual.	Due	to	these	two	design	differences,	our	study	is	not	completely	comparable	to	the	previous	findings.		A	further	limitation	that	should	be	noted	is,	that	the	weighted	MoCA	was	not	associated	to	other	non-motor	symptoms.	It	is	known	that	PD-MCI	patients	are	likely	to	develop	dementia	in	the	course	of	the	disease.	Moreover,	it	is	known	that	urological	symptoms,	as	well	as	PD-MCI	can	attribute	to	the	more	prone	 disease	 progression	 and	 earlier	 conversion	 to	 PDD	 (Williams-Gray	 et	 al.,	 2009;	Winge	 et	 al.,	
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2007).	In	the	second	study,	MoCA	did	not	contribute	to	the	PD-UU	independently.	However,	in	this	study	we	used	the	original	scoring	algorithm.	Future	studies	should	investigate	the	new	scoring	algorithm	in	association	to	other	non-motor	symptoms,	especially	PD-UU.				
Conclusion	
	In	conclusion,	this	thesis	investigated	the	role	of	cognitive	impairment	in	PD-UU,	using	a	comprehensive	neuropsychological	test	battery.	We	started	in	a	broad	unselected	PD	sample	and	shifted	our	focus	into	the	selected	sample,	excluding	PDD,	concomitant	diseases	and	medication	influencing	either	bladder	symptoms	or	cognition.	In	the	second	step,	a	new	scoring	algorithm	for	a	cognitive	test	battery-MoCA,	which	is	broadly	used	in	clinical	routine,	was	evaluated.			We	were	able	to	show	that	the	global	cognitive	level	and	visuo-construction	are	associated	to	PD-UU	in	more	 advanced	 stages	 of	 the	 disease.	 The	 executive	 function	 was	 associated	 to	 PD-UU	 in	 early	 to	moderate	stages	of	PD.	A	discriminant	analysis	allowed	to	describe	a	prototypical	PD-UU	patient,	who	would	suffer	from	a	higher	impairment	of	executive	functions,	a	higher	number	of	non-motor	symptoms	and	experience	changes	in	HRQoL	related	to	stigma,	when	compared	to	the	PD-NUU	patient.			Furthermore,	 findings	of	 this	 thesis	confirm	a	high	prevalence	of	urinary	dysfunction	among	the	PD	population.	 To	 our	 knowledge,	 these	 are	 the	 largest	 studies	 that	 investigated	 the	 role	 of	 cognitive	impairment	in	PD-UU	using	a	comprehensive	neuropsychological	test	battery.			With	 regard	 to	 the	 weighted	 MoCA,	 this	 thesis	 showed	 that	 the	 new	 scoring	 algorithm	 can	 detect	cognitive	 impairment	 in	 PD	more	 effectively	 than	 the	 original	MoCA,	 however,	 only	 if	 PD-MCI	was	classified	with	a	2	SD	cut-off.	Therefore,	the	weighted	MoCA	might	have	a	greater	discriminant	power	in	detecting	PD-MCI	patients	at	risk	of	PDD.	Our	findings	emphasize	the	need	for	further	evaluation	of	MoCA	in	order	to	improve	the	diagnosis	of	PD	patients	at	risk	for	future	PDD.	
	
 
Conclusion	/	Zusammenfassung	
 Parkinson	 ist	 die	 zweithäufigste	neurodegenerative	Erkrankung	 in	Europa,	mit	 einer	Prävalenz	 von	1.8%	ab	dem	55	Lebensjahr.	Zu	den	Kardinalsymptomen	gehören	Bradykinesie,	Rigor,	und	Ruhetremor.	Zusätzlich	 treten	 häufig	 nicht-motorische	 Symptome	 auf,	 die	 im	 Verlauf	 das	 Erkrankungsbild	dominieren	 können,	 eine	 höhere	 Beeinträchtigung	 des	 Alltags	 verursachen	 und	 von	 Patienten	 als	stärker	aversiv	wahrgenommen	werden.		
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Zu	den	häufigsten	nicht-motorischen	Symptomen	gehören,	unter	anderem,	autonome	Symptome	–	wie	Harndrang	 mit	 oder	 ohne	 begleitender	 Harninkontinenz,	 Störungen	 der	 Sexualität,	 orthostatische	Hypotension,	 oder	 kognitive	 Störung.	 Kognitive	 Störungen	 betreffen	 bis	 zu	 30%	 aller	 Patienten	(Aarsland,	Bronnick,	&	Fladby,	2011;	Aarsland	et	al.,	2009)	und	nach	acht	 Jahren	Erkrankungsdauer	beträgt	die	Wahrscheinlichkeit	an	einer	Demenz	zu	erkranken	etwa	78%	(Aarsland	et	al.,	2003).			Blasensymptome	können	bis	zu	60%	aller	PD	Patienten	 	(PD-UU)	betreffen	(Araki,	Kitahara,	Oida,	&	Kuno,	2000)	und	treten	signifikant	häufiger	als	bei	gesunden	Kontrollpersonen	auf.	Das	Vorkommen	wird	mit	der	motorischen	Progression,	als	auch	der	kognitiven	Beeinträchtigungen	in	Zusammenhang	gebracht.		Die	Ursache	der	Drangsymptomatik	bei	PD	ist	sehr	komplex.	Die	zentrale	Regelung	des	Miktionsreflexes	setzt	 sich	 aus	 Bahnen	 zwischen	 Frontalhirn	 und	 Basalganglien	 zusammen,	 die	 die	 Kontrolle	 und	interozeptiven	 Prozesse	 der	 Miktion	 modulieren	 (Kitta	 et	 al.,	 2015).	 Dieser	 Regelkreis,	 der	 an	emotionalen	 und	 Verhaltensaspekten	 der	 Miktion	 beteiligt	 sei,	 steuert	 generell	 das	 menschliche	Verhalten,	 insbesondere	 unsere	 exekutiven	 Fähigkeiten,	wie	 Inhibition,	Monitoring	 und	Update	 der	wahrgenommenen	 Signale	 (Fowler,	 Griffiths,	 &	 de	 Groat,	 2008).	 	 Der	 Zusammenhang	 zwischen	kognitiver	 Verschlechterung	 und	 den	 PD-UU	 lässt	 sich	 also	 auf	 Ebene	 der	 Architektur	 kortikaler	Netzwerke	ableiten.		Der	Hauptfokus	dieser	Dissertation	lag	darin,	die	Rolle	der	Kognition	in	PD-UU	zu	überprüfen.	Die	erste	Arbeit,	 die	 in	 einer	 unselektierten	 Kohorte	 von	 PD	 Patienten	 durchgeführt	 wurde,	 bestätigt	 hohe	Prävalenzratte	der	PD-UU	–	etwa	57%	der	eingeschlossenen	Patienten	berichteten	von	unspezifischen	Blasenproblemen.	 Weiterhin	 wurde	 das	 Auftreten	 von	 PD-UU	 mit	 Beeinträchtigung	 des	 globalen	kognitiven	 Status,	 sowie	 Visuo-konstruktiven	 Fähigkeiten	 und	 Schwierigkeiten	 in	 der	Alltagsbewältigung	assoziiert.			Die	 zweite	 Arbeit	 baut	 auf	 den	 Ergebnissen	 der	 ersten	 Arbeit	 auf,	 wobei	 die	 Limitationen	 aus	 der	explorativen	Analyse	weitgehend	aufgehoben	wurden.	Die	Forschungsfrage	richtete	ihren	Fokus	darauf,	ob	es	möglich	wäre,	einen	prototypischen	PD-UU	Patienten	anhand	seiner	nicht-motorischen	Merkmale	zu	 identifizieren.	 Ein	 prototypischer	 PD-UU	 Patient	 wies	 Beeinträchtigungen	 der	 exekutiven	Funktionen	 auf,	 hatte	 eine	 hohe	 Anzahl	 an	 anderen	 nicht-motorischen	 Symptomen	 und	 berichtete	niedrige	Stigma,	bezogen	auf	die	Lebensqualität	(Health	related	Quality	of	Life,	HRQoL).	Die	Zuordnung	der	 aufgezeigten	 Gruppenmerkmale	 wurde	 mithilfe	 von	 der	 Diskriminanzanalyse	 überprüft,	 deren	Kombination	mit	hoher	diagnostischer	Genauigkeit	von	72.4%	einen	PD-UU	Patienten	charakterisierte.		Die	 zweite	 Hauptfrage	 dieser	 Promotion	 beschäftigt	 sich	 mit	 dem	 Thema	 der	 Validierung	 eines	Algorithmus,	 der	 für	 ein	 Screening	 Tool-MoCA	 (Montreal	 Cognitive	 Asessment)	 entwickelt	 wurde	(Fengler	et	al.,	2016).	Wir	validierten	den	neuen	Algorithmus	und	überprüften	dessen	Sensitivität	und	Spezifität,	 kognitive	 Veränderungen	 zu	 diagnostizieren,	 in	 einer	 nicht	 dementen	 PD	 Kohorte.	
	 25 
Identifikation	der	leichten	kognitiven	Beeinträchtigung	in	PD	(PD-MCI)	ist	von	hoher	Bedeutung,	weil	die	 Konversionsrate	 zur	Demenz	 dadurch	 erhöht	wird	 (Williams-Gray	 et	 al.,	 2009).	 Der	MoCA-Test	wurde	 als	 ein	 sensitives	 Tool	 für	 das	 Entdecken	 von	 leichten	 kognitiven	 Beeinträchtigungen	 und	Demenz	bei	Alzheimer	Patienten	konzipiert	(Nasreddine	et	al.,	2005).	Durch	Validierungsstudien	ist	es	aber	zu	einem	der	wichtigsten	Screening	Tools	im	Bereich	der	PD	geworden(Hoops	et	al.,	2009).	Ein	neuartiger	 Gewichtungsalgorithmus	 zeigte	 einen	 diagnostischen	 Vorteil	 gegenüber	 der	 originalen	MoCA.	 In	 einer	 nicht	 dementen	 PD	 Kohorte	 konnten	 wir	 zeigen,	 dass	 der	 Cut-Off	 von	 zwei	Standardabweichung	die	größte	Trennschärfe	aufzeigte	und	mit	hoher	Sensitivität	PD-MCI	Patienten	identifiziert,	die	Risiko	für	Konversion	zu	Demenz	aufzeigen.				
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Abstract		
	Urinary	dysfunction	(UD)	is	a	common	non-motor	feature	of	Parkinson’s	Disease	(PD),	and	might	be	secondary	 to	 neurodegeneration	 involving	 cortical	 and	 subcortical	 brain	 areas.	 The	 possible	 link	between	UD	and	cognitive	deficits	has	never	been	examined	in	frontal	cortex	impairment,	and	is	still	not	completely	understood	in	PD.		In	 the	 present	 study,	 94	 PD	 patients	 underwent	 a	 comprehensive	motor,	 cognitive	 and	 non-motor	assessment.	It	was	shown	that	55.3%	of	patients	reported	UD,	of	which	17%	needed	specific	urological	treatment.	 Patients	who	 reported	 UD	 performed	worse	 on	 global	 cognition	 (PANDA,	 p=.05),	 visuo-constructive	functions	(CERAD/praxis,	p=.03:	and	Figure	Test,	p=.03),	and	instrumental-activities-of-daily-living	 functions	 (IADL,	 p=.03),	 than	 patients	 without	 UD.	 The	 group	 with	 UD	 medication	performed	worse	on	global	cognition	(PANDA,	p=.02)	and	visuo-constructive	functions	(CERAD:	praxis,	
p=.05;	 CERAD:	 praxis	 recall	 p=.05)	 than	 the	 UD	 group	 without	 medication,	 independent	 of	 anti-cholinergic	treatment	effect.	Our	findings	suggest	an	association	between	cognitive	impairment	and	UD	in	PD	independent	from	symptomatic	treatment.		
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Background	
	Non-motor	 symptoms	 are	 now	 recognised	 as	 part	 of	 the	 typical	 features	 of	 Parkinson’s	 disease,	increasing	 during	 stages	 of	 disease	 and	 influencing	 patients’	 and	 their	 caregivers’	 quality	 of	 life	(Martinez-Martin	et	al.	2011).		Urinary	dysfunction	(UD)	 is	a	common	non-motor	 feature	and	 is	 typically	characterized	by	urgency,	frequency,	 or	 nocturia	with	 little	 or	 no	 post-void	 residuals	 (Matthew	 Smith	 2015).	 Several	 reports	suggest	 that	 UD	 is	 twice	 as	 common	 in	 PD	 than	 in	 the	 general	 population,	 occurring		in	 27%	 to	 64%	 of	 patients	 (Winge	 and	 Fowler	 2006;	 Winge	 and	 Nielsen	 2012),	 according	 to	 the		different	 cohorts	 and	 diagnostic	 tools.	 A	 high	 prevalence	 of	 UD	 was	 reported	 for		PD	 dementia	 (PDD)	 and	 dementia	 with	 Lewy	 Bodies	 (Sakakibara	 et	 al.	 2014;	 Tateno	 et	 al.	 2015),	suggesting	a	possible	association	between	this	symptom,	cognitive	 impairment	and	the	spreading	of	cortical	alpha-synuclein.		The	presence	of	urinary	dysfunction	(UD)	appears	to	be	modulated	by	patient’s	age,	disease	duration,	concomitant	medication,	 and	 severity	 of	 motor	 symptoms	 (Sakakibara	 2008).	 It	 is	 known	 that	 the	frontal	basal	ganglia	D1	dopaminergic	circuit,	which	suppresses	the	micturition	reflex	in	a	healthy	brain,	is	abnormal	in	PD	(Winge	and	Nielsen	2012).	Apart	from	peripheral	and	basal	ganglia	involvement,	the	influence	 of	 higher	 cortical	 areas	 has	 been	 discussed	 (Sakakibara	 et	 al.	 2014),	 with	 neuroimaging	studies	showing	that	 frontal	cortical	regions	are	 involved	 in	controlling	 the	micturition	(Fowler	and	Griffiths	2010).	There	is	evidence	that	the	neural	circuits	in	frontal	areas	controlling	human	behaviour,	such	as	those	involved	in	decision	making,	attention	processes,	and	integration	of	extrinsic	input,	also	participate	in	urinary	control	(Blackett	et	al.	2009).	Therefore,	PD	patients	whose	cognition,	especially	in	 frontal	 lobe	 functions,	 is	 affected,	might	be	of	 higher	 risk	 for	UD,	 since	both	bladder	 control	 and	cognition	 originate	 from	 the	 same	 brain	 lesions.	 Investigating	 this	 possible	 link	 is	 the	 aim	 of	 this	explorative	pilot	study.				
Patients	and	Methods	
	
Participants		We	included	94	patients	with	idiopathic	PD	according	to	the	United	Kingdom	Brain	Bank	criteria,	who	were	recruited	from	the	outpatient	clinic	of	the	University	hospital	of	Tübingen	(Liepelt-Scarfone	et	al.	2012).	The	study	included	patients	who:	i)	were	older	than	50	years,	ii)	had	optimized	medication,	iii)	had	adequate	or	corrected	hearing/visual	abilities,	and	iv)	with	German	as	mother	tongue.	Exclusion	criteria	were:	a)	other	neurological	diseases	affecting	the	central	nervous	system,	b)	prior	surgery	for	PD,	and	c)	
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MMSE	<	18	(the	above	limit	suggested	by	the	local	committee	to	sign	an	informed	consent).	The	local	ethics	committee	approved	the	study.	Informed	consent	was	obtained	from	all	individual	participants.	
 
Assessments		We	 obtained	 demographics	 and	 a	 full	 drug	 history,	 which	 included	 the	 total	 daily	 dose	 of	 all	dopamimetics	 [expressed	 by	 the	 levodopa	 equivalent	 daily	 dose	 (LEDD)	 (Tomlinson	 et	 al.	 2010)],	monoamine	oxidase,	and	dopamine	agonist	medication	(Winge	et	al.	2004).	We	computed	a	possible	adverse	 effect	 of	 medication-as	 well	 parkinsonian	 as	 non-parkinsonian,	 expressed	 by	 the	anticholinergic	risk	scale	(ARS),	as	suggested	by	Crispo	and	colleagues	(Crispo	et	al.	2016).	Patients	taking	anticholinergics,	which	can	have	a	negative	influence	on	cognition,	were	excluded	from	further	analyses.	Motor	function	was	evaluated	using	the	Unified	Parkinson’s	Disease	Rating	Scale	(UPDRS)	Part	III	(Fahn	et	al.	1987)	and	the	modified	Hoehn-Yahr	scale.			Presence	and	severity	of	UD	was	scored	on	a	5	point	scale	(0-	normal	urinary	function,	1-increase	in	urgency	and/or	frequency,	no	drug	treatment	required,	2-	urgency	and/or	frequency,	drug	treatment	required,	 3-	 urge	 incontinence	 and/or	 incomplete	 bladder	 emptying	 needing	 intermittent	catheterization,	and	4-	incontinence	needing	indwelling	catheter)	(Wenning	et	al.	2004).	A	scale	score	≥1	was	defined	as	UD.	Patients	with	a	catheter	(score	≥3)	were	excluded	 from	further	analyses	(for	demographic	 data	 see	 Supplementary	 Table	 1)	 as	 this	 treatment	 is	 only	 rarely	 needed	 in	 PD	 and	therefore	suggests	a	urologic	condition	as	the	cause	(Sakakibara	et	al.	2012).		To	 assess	 the	 major	 areas	 of	 subcortical-frontal	 and	 cortical	 mediated	 functions	 affected	 in	 PD,	 a	comprehensive	test	battery	was	used	(Dubois	et	al.	2007)	(see	Table	2	for	details).	Parkinson’s	disease	dementia	 (PDD)	was	diagnosed	according	 to	 the	Level	 II	 criteria	of	 the	Movement	Disorder	Society	(MDS)	Task	Force	(Emre	2007).	As	the	language	domain	was	only	assessed	with	one	test,	diagnosis	of	mild	cognitive	 impairment	 (PD-MCI)	was	made	by	use	of	 the	Level	 I	 criteria	of	 the	MDS	Task	Force	criteria		(Litvan	et	al.	2012).	Based	on	the	neuropsychological	test	data,	PD-MCI	patients	were	further	subdivided	 into	those	with	single	domain	MCI	(one	test	within	one	cognitive	domain	≤	1.5	standard	deviation	below	the	population	norm	described	in	the	handbooks	of	each	test)	or	multiple	PD-MCI	(at	least	 two	 tests	 in	 two	 different	 cognitive	 domains	 below	 cut-off,	 see	 Table	 1	 for	 further	 details).	Additionally,	self-reported	memory	status	was	evaluated	using	the	Memory	Assessment	Clinical	Self-Report	 (subscales:	 retention,	 long	 term	 memory,	 digit	 memory,	 daily	 memory,	 verbal	 skill	 and	constructive	skills)	(Crook	and	Larrabee	1992).	The	total	score	of	the	Beck	Depression	Inventory-I	(BDI)	(Hautzinger	 et	 al.	 1995)	 was	 used	 to	 identify	 depressive	 symptoms.	 Presence	 and	 severity	 of	neuropsychiatric	symptoms	was	assessed	by	the	Neuropsychiatric	 Inventory	(NPI)	(Cummings	et	al.	1994).	Activities	of	 instrumental	daily	living	impairment	(IADL)	were	investigated	by	using	the	total	score	 of	 the	 Lawton	 Instrumental	 Activities	 of	 Daily	 Living	 (Lawton-IADL)(Graf	 2009)	 and	 the	Nürnberger-Alters	Aktivitäten	Inventory	(NAA-IADL)	(Oswald	1999).		
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Statistical	analysis	
	Data	were	analysed	using	SPSS	22	for	Windows	(SPSS	Inc,	Chicago,	IL,	USA).	Motor	and	demographic	characteristics	and	prevalence	of	cognitive	diagnosis	of	all	UD	subgroups	were	analysed	using	either	Mann-Whitney-Tests	or	χ²-statistics	(p<0.05	indicating	differences	between	groups).	A	Mann-Whitney-U	Test	was	used	for	the	comparison	of	cognition	and	IADL	functions	between	UD	and	no-UD	groups.	For	the	UD	positive	groups	(treatment	vs.	no	treatment),	a	binary	regression	with	cognitive	test	or	IADL	test	as	the	dependent	variable	and	group	membership	as	the	independent	variable	was	used.	Gender	and	education	years	were	included	into	the	model	as	cofounders.	Post-hoc	testing	was	done	with	the	Holm-Bonferroni	adapted	alpha	level	(p=.006	for	Lawton	IADL	and	p=.004	for	NPI).	A	non-parametric	Mann-	Whitney-U	test	was	performed	to	identify	the	association	between	IADL	impairment	and	the	cognitive	diagnosis	(no	cognitive	impairment	(PD-NC)	vs.	PD-MCI	vs.	PDD).	Further,	a	non-parametric	regression	analysis	 was	 performed	 to	 specify	 the	 primary	 cause	 on	 IADL	 impairment	 including	 the	 cognitive	diagnosis	 (PD-NC	vs.	PD-MCI	vs.	PDD)	as	 independent	variables,	and	 the	UD	score,	UPDRS-III	 score,	gender	and	education	years	as	covariates.	
	
	
Results		Hundred	PD	patients	fulfilled	the	criteria	for	PD	and	were	recruited	into	the	study.	Mean	age	was	71	(range:	 56-89	 years),	 with	 52	 (55.3%)	 patients	 reporting	 UD.	 Sixteen	 (17%)	 of	 examined	 patients	received	 drug	 treatment	 of	UD.	 Four	 patients	 (4.3%)	 had	 a	 catheter	 (score	 ≥3,	 all	 female)	 and	 two	received	anticholinergic	medication,	which	 is	known	 to	 influence	cognitive	performance	 in	negative	matter,	were	therefore	excluded	from	further	analyses.	Data	of	94	patients	were	included	into	the	final	analysis.		Of	all	94	PD	patients,	74	(78.7%)	were	medicated	with	dopamine	agonists-of	whom	8	(10.8%)	received	dopamine	agonists	as	a	monotherapy.	Twenty	(21.3%)	of	all	patients	received	MAO-inhibitors,	of	whom	9	 (45.0%)	 as	 monotherapy;	 and	 78	 (83.0%)	 received	 levodopa,	 out	 of	 whom	 11	 (87.0%)	 with	 a	combination	of	other	dopaminomimetics.	Regarding	the	level	of	LEDD,	MAO-inhibitors	and	dopamine	agonist,	we	found	no	significant	difference	between	our	study	groups	(see	Table	1	for	details).			The	study	groups	differed	significantly	in	gender	distribution	and	educational	level	(Table	1).	Therefore,	these	were	included	as	confounders	for	further	analyses.	In	our	population,	only	higher	educated	males	were	 more	 likely	 to	 receive	 UD	 drug	 treatment,	 including	 antispasmodic	 agents	 (n=3),	 herbal	medications	 (n=5)	 or	 alpha	 blockers	 (n=8).	 Our	 groups	 did	 not	 differ	 in	 the	 number	 of	 patients	diagnosed	as	PD-MCI	or	PDD	 (p>.05,	 see	Table	1).	Also	PD-MCI	 subtype	 classification	did	not	differ	statistical	significantly	(p>.05)	between	our	study	groups,	with	the	following	prevalence:	PD-MCI	single	
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(19.0%	of	PD	no-UD,	16.6%	of	UD-non	medicated	and	18.7%	of	UD-medicated);	PD-MCI	multiple	(47.7%	of	PD	no-UD,	47.2%	of	UD-non	medicated	and	56.3%	of	UD-medicated).		Patients	 who	 reported	 UD	 showed	 lower	 cognitive	 performances	 as	 reflected	 by	 the	 Parkinson	Neuropsychometric	Dementia	Assessment	(PANDA,	p=.05),	Nuernberger	Altersinventar	(NAI)	subtest	Figure	 Test	 (p=.03),	 and	 the	 Praxis	 subtest	 of	 the	 Consortium	 to	 establish	 a	 Registry	 of	 Alzheimer	Disease	(CERAD)	plus	battery,	(p=.03)	compared	to	patients	with	no	UD.	They	had	lower	scores	in	the	Lawton-IADL	scale	than	in	those	without	UD	(p=.03).	Post-hoc	comparisons	(Holm-Bonferroni	method)	of	the	IADL	item	profile	between	patients	who	reported	UD	and	those	without	UD	revealed	differences	in	financial	management	(p=.005).		The	comparison	analysis	for	patients	who	reported	UD	(patients	with/without	urological	medication)	showed	 following	 results:	 patients	 with	 medical	 treatment	 showed	 lower	 cognitive	 performance	reflected	 by	 PANDA	 (p=.02),	 Praxis	 subtest	 of	 CERAD	 (p=.05)	 and	 for	 the	 Praxis	 Recall	 (p=.05).	 An	overall	effect	in	IADL	or	NPI	scale	was	not	found.	No	statistical	group	differences	were	found	for	the	self-reported	memory	complains	assessed	by	the	MAC-S	scale.		In	 our	 post-hoc	 analysis	we	 found	 that	 PD-NC	 had	 higher	 scores	 (median	 23,	 14-24	 points)	 on	 the	Lawton	IADL	scale	than	both	PD-MCI	(median	22,	11-24,	p=.008)	and	PDD	patients	(median	18,	10-24	points,	p<.001).	Moreover,	PD-MCI	and	PDD	patients	differed	in	their	Lawton	IADL	scores	(p=.004).	To	evaluate	if	the	effect	on	IADL	functions	was	primarily	caused	by	cognitive	or	bladder	dysfunction,	we	performed	a	non-parametric	 regression	analysis	with	 cognitive	groups	as	 independent	variable,	 the	UPDRS	III	Score,	the	UD	score,	gender	and	education	years	as	covariates;	and	the	total	Lawton	IADL	total	as	dependent	variable.	As	expected,	performance	of	the	three	groups	differed	in	their	total	Lawton	IADL	scores	as	follows:	p=.04	for	PD-NC	vs.	PD-MCI,	p=.001	for	PD-NC	vs.	PDD	and	p=.004	for	PD-MCI	vs.	PDD.	We	found	that	even	if	 the	cognitive	 impairment	was	a	strong	predictor	of	 IADL	function,	also	motor	performance	(p<.001)	as	well	as	gender	(p=.02)	were	significantly	associated	to	the	total	Lawton	IADL	score.	UD	did	not	achieve	significance	level	(p=.06).			
Discussion		Urinary	 dysfunction	 in	 PD	 has	 received	 increasing	 attention	 in	 the	 past	 years,	 due	 to	 the	 better	knowledge	of	non-motor	symptoms.	Our	data	confirms	the	high	UD	prevalence	in	PD	population	–	55%	reported	UD,	with	17%	receiving	UD	drug	treatment	(Araki	and	Kuno	2000;	Winge	and	Fowler	2006).	Our	prevalence	rate	is	in	accordance	with	previous	data,	confirming	that	UD	is	recognized	as	a	common,	non-motor	problem	of	PD.	However	the	limited	sample	size	should	be	acknowledged	when	reviewing	the	results.		
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To	 examine	 the	 UD	 symptoms,	 we	 used	 self-report	 questionnaires,	 which	 are	 often	 used	 to	 assess	urinary	problems	in	PD	(Wenning	et	al.	2004;	Winge	and	Fowler	2006;	Winge	and	Nielsen	2012).	Even	though	our	groups	did	not	differ	in	the	motor	scale	scores	(UPDRS	III	and	H&Y	Scales),	we	cannot	rule	out	 that	 the	 reported	 urinary	 problems	 might	 be,	 at	 least	 partly,	 caused	 by	 motor,	 especially	 gait	disorders	or	other	concomitant	diseases.	Future	studies	should	assess	the	potential	influence	of	these	factors.	To	exclude	other	physical	causes	leading	to	UD,	urological	examinations	should	be	taken	into	account.		It	 is	 known	 that	 PD	 medication	 may	 influence	 bladder	 function	 in	 PD	 patients.	 Previous	 findings	reported	a	vast,	yet	unpredictable	influence	of	dopamine	agonists	on	urodynamic	parameters.	As	our	study	 groups	 did	 not	 differ	 in	 their	 daily	 dose	 of	 varying	 dopamine	 agonists,	 MAO-	 inhibitors	 or	levodopa	levels,	we	did	not	control	for	medication	intake.	Since	no	statistical	difference	was	found,	we	assume	that	the	type	of	medication	was	not	the	primary	cause	of	UD	in	our	sample.		As	studies	have	shown	that	use	of	anticholinergic	medication	may	affect	cognitive	function	in	PD	(Ehrt	2010),	we	decided	to	exclude	this	small	group	of	PD	patients	from	our	analysis.	However,	latter	findings	(Crispo	et	al.	2016;	Rudolph	et	al.	2008)	show	that	also	the	adverse	effects	related	to	anticholinergic	medication	use	may	cause	negative	effects	in	older	patients.	In	our	study	we	compared	all	medications	in	our	cohorts,	using	the	ARS-Scale	as	recommended	by	Crispo	and	colleagues	(Crispo	et	al.	2016).	We	did	not	find	significant	differences	between	our	study	groups.	These	findings	strengthen	our	assumption	that	there	is	an	association	between	bladder	dysfunction	and	cognition	in	PD.		In	our	explorative	analysis,	patients	who	reported	UD	performed	worse	in	global	cognition	(executive	and	 visuo-constructive	 functions),	 than	 patients	 with	 no	 UD	 complaints.	 Moreover,	 patients	 who	received	UD	drug	treatment	showed	more	impairment	in	global	cognitive,	as	well	as	in	executive,	visuo-constructive	and	IADL	functions,	compared	to	patients	without	UD.	 It	has	been	shown	that	different	cortical	regions	and	parts	of	the	frontal	lobe,	which	are	involved	in	modulating	aspects	of	cognition	and	emotions,	are	also	involved	in	the	control	processes	of	bladder	control	(Fowler	and	Griffiths	2010).	In	general,	urinary	function	is	influenced	by	a	complex	neural	system,	located	in	the	brain,	spinal	cord,	and	peripheral	autonomic	ganglia.	The	forebrain’s	activation	of	a	voluntary	voiding	is	being	modulated	by	the	basal	ganglia	and	brain	stem	circuitry	(de	Groat	et	al.	2015;	Kitta	et	al.	2016).	In	PD,	central	nervous	system	pathology	is	clearly	related	to	UD	problems	and	should	be	further	examined	on	a	cortical	as	well	as	a	subcortical	level.		Depression	and	anxiety	are	also	known	to	worsen	bladder	function	(Sakakibara	et	al.	2013),	however	our	study	could	not	confirm	these	findings.	Within	our	study	population,	no	difference	was	found	for	neuropsychiatric	symptoms,	neither	 for	the	total	score,	nor	 for	the	 individual	subscale	comparisons.	Further	examinations	are	required,	as	the	associations	could	build	a	more	heterogenic	phenotype	of	PD	(Fereshtehnejad	et	al.	2015).		
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Our	findings	show	that	there	is	a	connection	between	impairment	in	cognitive	functions	and	UD	in	PD.	The	link	between	autonomic	dysfunction	(orthostatic	hypotension)	and	cognition	has	been	explored	in	previous	studies	(Pilleri	et	al.	2013).	Since	autonomic	dysfunction	might	appear	before	PD	onset,	or	during	the	disease	course,	whilst	cognitive	dysfunction	rate	increases	with	disease	duration	(Liepelt-Scarfone	 et	 al.	 2015),	 it	 is	 important	 for	 future	 studies	 to	 explore	 if	 this	 complex	 relationship	 is	associative	or	causative.	In	our	group,	UD	was	associated	with	cognitive	dysfunction,	independent	of	disease	 duration	 and	 anti-cholinergic	 effects.	 A	 higher	 UD	 impairment	 was	 associated	 with	 higher	impairment	in	cognition,	which	implies	that	UD	itself	might	be	an	important	marker	for	PDD.	To	specify	the	analyses,	we	divided	our	cohort	as	mentioned	earlier.	Although	we	 included	cofounders	such	as	gender	 and	 education	 years,	 we	 could	 not	 completely	 exclude	 that	 other	 concomitant	 medical	conditions	influenced	UD	in	our	sample;	therefore	our	pilot	data	need	to	be	confirmed	in	future	studies.			Previous	 studies	 show	 that	 PD	 patients	 may	 experience	 abnormal	 urodynamic	 functions	 without	reporting	UD	(Araki	and	Kuno	2000;	Uchiyama	et	al.	2011).	In	these	findings,	patients	did	not	contribute	to	any	impairment	in	IADL.	However,	in	order	to	score	on	the	questionnaire,	patients	must	acknowledge	and/	or	be	bothered	by	a	given	symptom,	and	/or	need	to	be	stressed	by	the	compensatory	mechanisms	(Winge	et	al.	2004).	As	group	classification	in	this	study	was	primarily	based	on	patients’	reports,	we	cannot	exclude	the	possibility	that	presence	of	asymptomatic	UD	might	affect	cognitive	performance.	Future	 studies	 should	 therefore,	 include	 urological	 examinations	 to	 exclude	 possible	 concomitant	factors	of	UD	in	PD.		In	general,	patients	with	UD	reported	having	more	problems	in	their	activities	of	daily	living	than	those	with	no	UD.	Hence,	 impairment	 of	 IADL	 function	might	 be	 an	 indicator	 for	 accompanying	 cognitive	worsening.	It	was	shown	that	even	mild	cognitive	impairment,	which	precedes	PDD	in	many	cases,	is	associated	with	IADL	problems	(Leroi	et	al.	2012).	In	our	post	hoc	analysis	we	found	that	only	cognitive	and	motor	impairment	influence	the	perceived	worsening	of	IADL	in	a	negative	matter.	Our	analysis	therefore	showed	that	severity	of	UD	did	not	additionally	contribute	to	the	reported	IADL	problems.	Our	findings	are	in	accordance	with	results	from	Uchiyama	and	colleagues	(Araki	et	al.	2000;	Uchiyama	et	al.	2011),	who	also	 found	that	asymptotic	urinary	problems	did	not	affected	IADL	function	 in	PD.	However,	more	research	is	needed	to	clarify	the	link	between	cognitive	performance,	urinary	functions	and	the	profile	of	IADL	complaints	in	PD.			Our	 study	 groups	 did	 not	 differ	 in	 age,	 disease	 duration,	 or	motor	 severity.	 Previous	 studies	 showed	correlations	between	UD	and	either	disease	stage,	motor	severity	(Araki	and	Kuno	2000;	Yamamoto	et	al.	2009),	or	age	(Campos-Sousa	et	al.	2003),	while	others	failed	to	do	so	(Winge	et	al.	2006).	Higher	educated	males	were	more	likely	to	report	UD	drug	treatment	in	our	sample,	which,	even	if	statistically	corrected,	is	a	limitation	of	our	study.	Presence	and	severity	of	UD	might	be	of	great	heterogeneity,	unfortunately,	the	origin	and	UD	disease	onset	were	not	assessed	in	the	present	cohort.	Since	we	compared	parkinsonian	medication,	we	can	surely	rule	out	its	influence	on	UD	in	our	sample.	Future	studies	should	distinguish	in	more	detail	whether	the	occurring	symptom	can	be	related	to	other	primary	causes.		
	 8 
Our	 explorative	 analysis	 suggests	 that	 cognitive	 function	may	 be	 different	 in	 PD	 patients	with	 and	without	 UD.	 Since	 urinary	 autonomic	 dysfunctions	 are	 often	 difficult	 to	 medicate,	 a	 deeper	understanding	of	the	association	between	cognitive	worsening	and	UD	and	its	possible	causality	can	help	to	define	a	more	holistic	model	of	urinary	dysfunction	in	PD.			 	
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Table	1:	 Demographic	and	clinical	characteristics	of	subjects	with	and	without	self-reported	urinary	dysfunction	(UD)	
Variables	 Total	 No	UD	 UD	 p	value	no-UD	vs.	UD	 UD	without	treatment	 UD	with	treatment	 p	value		for	both		UD	groups	Number	of	Subjects,	n(%)	 94	(100%)	 42	(44.7%)	 52	(55.3%)	 	 36	(38.3%)	 36	(38.3%)	 	Male	gender,	n	(%)	 60	(63.8%)	 23	(54.8%)	 36	(69.2%)	 .10	 20	(55.5%)	 16	(100%)	 .003	Years	of	Age	 71.0	(56/89)	 71.1	(56/83)	 70.93(58/89)	 .86	 69.6	(58/84)	 72.7	(62/89)	 .25	Years	of	Education	 12.0	(8/20)	 12.0	(8/19)	 12	(8/20)	 .77	 11.0	(8/19)	 13.5	(11/19)	 .01	Years	of	Disease	duration	 6.4	(1.2/24.4)	 7.8		(1.2/19.4)	 5.86	(2.6/24.4)	 .88	 5.8	(2.6/22.9)	 6.4	(4.2/24.4)	 .82	PD-MCI,	n	(%)	 46	(48.9%)	 26	(50.0%)	 20	(47.6%)	 .48	 17(47.2%)	 9	(56.3%)	 .81	PDD,	n	(%)	 13	(13.8%)	 3	(7.1%)	 10	(19.2%)	 .10	 5	(13.9%)	 5	(31.3%)	 .23	LEDD	 615		(0/4273.5)	 552.5		(100/4273.5)	 620		(0/1661)	 .66	 620	(0/1650)	 655		(297/1661)	 .68	MAO	Daily	Dose	 0	(0/203.5)	 0	(0/203.5)	 0	(0/151)	 .75	 0	(0/150)	 0	(0/151)	 .87	Dopamine	Agonist	 74	(78.7%)	 33	(78.6%)	 41	(97.6%)	 .85	 29	(90.1%)	 12	(75%)	 .87	Dopamine	Agonist	Daily	Dose	 0	(0/203.5)	 0	(0/203.5)	 0	(0/150)	 .78	 0	(0/150)	 0	(0/52.5)	 .82	Pergolide	 0	(0/600)	 0	(0/0)	 0	(0/600)	 .23	 0	(0/600)	 0	(0/0)	 .12	Ropinirole	 0	(0/0)	 0	(0/0)	 0	(0/0)	 .17	 0	(0/480)	 0	(0/160)	 .93	Cabergoline	 0	(0/533)	 0	(0/533)	 0	(0/533)	 .39	 0	(0/0)	 0	(0/533)	 .19	Bromocriptine	 0	(0/0)	 0	(0/0)	 0	(0/0)	 	 0	(0/0)	 0	(0/0)	 	COMT	Inhibitior	 0	(0/0)	 0	(0/0)	 0	(0/0)	 .49	 0	(0/1)	 0	(0/1)	 .16	Selegeline	 0	(0/2)	 0	(0/2)	 0	(0/2)	 .83	 0	(0/2)	 0	(0/2)	 .52	ARS,	n	(%)	 	 	 	 .41	 	 	 .17		 1	 21	(22.3%)	 7	(16.7%)	 14	(26.8%)	 	 12	(33.3%)	 2	(12.5%)	 		 2-3	 59	(62.8%)	 29	(69.0%)	 30	(57.8%)	 	 18	(50.0%)	 12	(75.0%)	 		 4+	 14	(14.9%)	 6(14.3%)	 8	(15.4%)	 	 6	(16.7%)	 2	(12.5%)	 	Beck	Depression	Inventory	 9.0	(0/34)	 7.5	(0/34)	 9	(1/30)	 .48	 9.0	(1/20)	 6.0	(1/30)	 .56	Motor	performance	 	 	 	 	 	 	 	UPDRS	III	 31	(10/73)	 27.0	(10/73)	 34	(14/58)	 .50	 34	(15/53)	 33	(14/58)	 .81	Hoehn	&	Yahr	n	(%)	 	 	 	 .16	 	 	 .49		 1	 1	(1%)	 1	(2.4%)	 0	(0%)	 	 0	(0%)	 0	(0%)	 		 1.5	 5	(5.3%)	 3	(7.1%)	 2(3.8%)	 	 2(3.8%)	 1	(6.2%)	 		 2	 34	(36.9%)	 15	(35.7%)	 19	(36.5%)	 	 19	(36.5%)	 4	(25%)	 		 2.5	 14	(14.7%)	 2	(4.8%)	 12	(23.1%)	 	 12	(23.1%)	 4	(25%)	 		 3	 30	(31.6%)	 16	(38.1%)	 14	(26.9%)	 	 14	(26.9%)	 5	(31.3%)	 		 4	 10	(10.5%)	 5	(11.9%)	 5	(9.4%)	 	 5	(9.4%)	 2	(12.5%)	 		If	not	other	indicated	values	were	given	in	Median	(range);	post-hoc	comparison:	ano	UD	vs.	UD	without	treatment,	bno	UD	vs.	UD	with	treatment,	cUD	without	vs.	UD	with	treatment;	LEDD:	Levodopa	equivalence	daily	dose;	UPDRS	III:	Unified	Parkinson	Disease	Rating	Scale,	ARS:	Anticholinergic	Risk	Scale		 	
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Table	2:	 Neuropsychological	test	results.	
Assessments	 Total	 no-UD	 UD	 p	value	no-UD	vs.	UD	 UD	without	treatment	 UD	with	treatment	 p	value	for	both	UD	groups	Cognitive	Screening	Assessments	 	 	 	 	 	 	Global	Cognition:	 	 	 	 	 	 	 	PANDA	 21	(4/30)	 23	(5/30)	 19	(4/30)	 .05	 19	(4/30)	 16.5	(8/27)	 .02	MMSE	 27	(19/30)	 28	(19/30)	 27	(20/30)	 .42	 27	(20/30)	 26.5(22/30)	 .98	Executive	Domaine:	 	 	 	 	 	 	 	Tower	of	London	 41	(0/100)	 36	(0/99)	 42	(0/100)	 .81	 42	(0/100)	 31	(13/80)	 .90	CERAD-Verbal	Fluency	 -.60	(-3.7/1.3)	 -.65	(-1.9/0.9)	 -.6	(-.37/1.3)	 .55	 -.70	(-3.7/1.3)	 -.50	(-1.7/1.2)	 .59	Trail	Making	Test-Part	B	 -.50	(-3.1/3.3)	 -.45	(-3.1/2.8)	 -.50	(-3.0/3.3)	 .99	 .20	(-3.0/3.1)	 -1.2	(-3.0/3.3)	 .25	Working	Memory:	 	 	 	 	 	 	 	WMSR-Digit	Span	forward	 53	(2/99)	 53	(2/98)	 53	(5/99)	 .58	 53	(5/99)	 53	(11/98)	 .85	WMSR-Digit	Span	backwards	 27	(2/94)	 45.5	(2/85)	 27	(2/94)	 .12	 27	(2/93)	 27	(2/94)	 .60	Attention:	 	 	 	 	 	 	 	TAP-Go/No	Go,	Median	RT		 42	(0/	99)	 46	(0/	99)	 31	(0/99)	 .51	 34	(0/94)	 31	(2/99)	 .96	Trial	Making	Test	Part	A	 -.50	(-3.3/3.2)	 -.50	(-3.3/1.9)	 -.70	(-3.1/3.2)	 .52	 -.60	(-3.3/3.2)	 -1.5	(-3.1/.60)	 .27	Memory:	 	 	 	 	 	 	 	-Word-List	Learning		 -.80	(-3.7/2.1)	 -.30	(-3.7/1.9)	 -.60	(-3.3/2.1)	 .66	 -.90	(3.6/	2.1)	 -1.2	(-3.4/	1.7)	 .38	-Word-List	Recall		 -.50	(-3.3/2.2)	 -.10	(-2.5/1.9)	 -.60	(-3.3/	2.2)	 .18	 -.60	(-3.3/2.2)	 -.50	(-2.1/	1.6)	 .21	-Word-List	Recognition	 .50	(-3.2/1.4)	 .50	(-3.1/1.4)	 .40	(-3.2/	1.4)	 .79	 .50	(-3.2/1.1)	 -.75	(-2.2/1.0)	 .75	-Logical	Memory	I		 18	(0/98)	 13	(2/98)	 25	(0/98)	 .42	 13	(1/98)	 23.5	(0/85)	 .27	-Logical	Memory	II		 22	(0/99)	 12	(2/99)	 25	(0/97)	 .22	 22	(0/97)	 39(0/77)	 .15	Language:	 	 	 	 	 	 	 	CERAD-Boston	Naming	Test	 -.30	(-3.0/1.6)	 -.05	(-3.0/1.4)	 -.50	(-3.0/	1.6)	 .07	 -.30	(-3.0/1.6)	 -.50	(-2.1/1.1)	 .94	Visuo-Construction:	 	 	 	 	 	 	 	CERAD-Praxis	 -1.1	(-4.7/1.5)	 -1.0	(-3.6/1.3)	 -1.0	(-4.7/	1.5)	 .03	 -1.4	(-4.7/1.5)	 -2.0	(-4.2/.09)	 .05	CERAD-Praxis	Recall	 -.80	(-4.1/2.2)	 -.50	(4.1/2.2)	 -1.0	(-3.5/	1.8)	 .08	 -1.0	(-3.5/1.8)	 -0.8	(-4.1/2.2)	 .05	Object	decision	 38.1(0/100)	 39.7(0/91)	 38.1(2/100)	 .27	 38.1(5/100)	 38.1(2/76)	 .77	Figure	test	 56(0/95)	 65(0/95)	 45	(3/92)	 .03	 45(5/88)	 40.5(0/92)	 .63	Berlin	Apraxia	Test	 34(17/24)	 33(20/40)	 34	(17/	42)	 .78	 34(17/24)	 35.5(25/41)	 .78	Activity	of	Daily	Living	Assessments:	 	 	 	 	 	 	Lawton	IADL	scale	 23	(10/24)	 23(11/24)	 22	(10/24)	 .03	 23(15/24)	 19.5(10/24)	 .09	NPI	Total	 7	(0/50)	 6	(0/45)	 7	(0/50)	 .74	 7(0/34)	 7.5	(0/50)	 .14	Delusion	 0	(0/12)	 0	(0/9)	 0	(0/12)	 .87	 0	(0/2)	 0	(0/12)	 .29	Hallucination	 0	(0/12)	 0	(0/9)	 0	(0/12)	 .80	 0	(0/12)	 0	(0/12)	 .99	Arousal	 0	(0/9)	 0	(0/9)	 0	(0/9)	 .29	 0	(0/2)	 0	(0/9)	 .04	Depression	 0	(0/9)	 .50	(0/9)	 0	(0/8)	 .08	 0	(0/8)	 0	(0/8)	 .97	Anxiety	 0	(0/9)	 0	(0/9)	 0	(0/8)	 .09	 0	(0/8)	 0	(0/2)	 .69	Euphoria	 0	(0/3)	 0	(0/1)	 0	(0/3)	 .46	 0	(0/3)	 0	(0/0)	 .51	Apathy	 0	(0/9)	 0	(0/8)	 0	(0/9)	 .72	 0	(0/8)	 0	(0/9)	 .19	Disinhibition	 0	(0/4)	 0	(0/3)	 0	(0/4)	 .02	 0	(0/4)	 0	(0/2)	 .82	Irritability	 0	(0/12)	 0	(0/12)	 0	(0/9)	 .35	 0	(0/9)	 0	(0/6)	 .60	Motor	movement	 0	(0/8)	 0	(0/8)	 0	(0/3)	 .69	 0	(0/3)	 0	(0/0)	 .32	Sleep	 0	(0/8)	 0	(0/12)	 0	(0/3)	 .25	 0	(0/8)	 2	(0/12)	 .36	Appetite	 0	(0/12)	 0	(0/12)	 0	(0/8)	 .49	 0	(0/8)	 0	(0/8)	 .31		
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All	values	are	given	as	median	and	range;	Berlin	Apraxia	Test	 (Liepelt-Scarfone,	 I.	 (2007).	Der	Berliner-Apraxie-Test	für	ideomotorische	und	ideatorische	Apraxie	-	Bestimmung	der	Itemkennwerte.	Zeitschrift	für	
Neuropsychologie,	18(3),	193-206);	Consortium	to	Establish	Registry	for	Alzheimer’s	Disease	(CERAD-plus,	Memory	 Clinic-NPZ	 (2005).	 The	 Consorium	 to	 Establish	 a	 Registry	 of	 Alzheimer's	Disease	 CERAD-Plus.	Basel:	 Memory	 Clinic-NPZ);	 Lawton	 IADL:	 Lawton	 Instrumental	 Activity	 of	 Daily	 Living	 Function	 scale;	
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Abstract		Introduction:	The	early	diagnosis	of	mild	cognitive	impairment	(PD-MCI)	in	Parkinson’s	disease	(PD)	is	essential	as	it	increases	the	future	risk	for	PD	dementia	(PDD).	Recently,	a	novel	weighting	algorithm	for	the	Montreal	Cognitive	Assessment	(MoCA)	subtests	has	been	reported,	to	best	discriminate	between	those	with	and	without	cognitive	impairment	in	PD.	The	aim	of	our	study	was	to	validate	this	scoring	algorithm	in	a	large	sample	of	non-demented	PD	patients,	hypothesizing	that	the	weighted	MoCA	would	have	a	higher	diagnostic	accuracy	for	PD-MCI	than	the	original	MoCA.		Methods:	 In	202	non-demented	PD	patients,	we	evaluated	cognitive	status,	clinical	and	demographic	data,	 as	well	 as	 the	MoCA	with	a	weighted	and	unweighted	score.	Receiver	Operating	Characteristic	(ROC)	curve	analysis	was	used	to	evaluate	discriminative	ability	of	the	MoCA.	Group	comparisons	and	ROC	analysis	were	performed	for	PD-MCI	classifications	with	a	cut-off	≤	1,	1.5,	and	2	standard	deviation	(SD)	below	appropriate	norms.		Results:	 PD-MCI	 patients	 scored	 lower	 on	 the	weighted	 than	 the	 original	MoCA	version	 (p	<	0.001)	compared	 to	 PD	 patients	 with	 normal	 cognitive	 function.	 Areas	 under	 the	 curve	 only	 differed	significantly	for	the	2	SD	cut-off,	leading	to	an	increased	sensitivity	of	the	weighted	MoCA	score	(72.9%	vs.	70.5%)	and	specificity	compared	to	the	original	version	(79.0%	vs.	65.4%).			Conclusions:	Our	results	indicate	better	discriminant	power	for	the	weighted	MoCA	compared	to	the	original	for	more	advanced	stages	of	PD-MCI	(2	SD	cut-off).	Future	studies	are	needed	to	evaluate	the	predictive	value	of	the	weighted	MoCA	for	PDD.			Keywords:	 Parkinson’s	disease,	cognition,	screening	assessment,	MoCA			 	
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Introduction		Parkinson’s	disease	(PD)	is	the	second	most	common	neurodegenerative	disease	 in	Europe	[1].	First	described	as	a	movement	disorder,	it	is	now	known	PD	patients	also	suffer	from	a	variety	of	non-motor	symptoms.	Loss	of	cognitive	functions	is	very	common	in	PD,	even	in	the	early	disease	stages	[2,3].	In	the	non-demented	PD	population,	around	27%	show	signs	of	mild	cognitive	impairment	(PD-MCI)	[4].	Early	and	valid	detection	of	PD-MCI	is	increasingly	regarded	as	very	important	in	clinical	practice,	due	to	its	predictive	value	for	Parkinson’s	disease	dementia	(PDD)	[5].	Furthermore,	cognitive	decline	has	a	strong	effect	on	patients’	quality	of	life	[6],	often	leading	to	nursing	home	placement	and	increased	risk	of	mortality	 [7].	Therefore,	an	early	and	valid	diagnosis	of	 cognitive	 impairment	 in	 the	daily	clinical	routine	 is	 crucial.	 However,	 identifying	 PD-MCI	 accurately	 in	 a	 clinical	 interview	 alone	 seems	 to	 be	inadequate	[8].	A	sensitive	test,	economic	in	time,	is	needed.			Several	screening	tools	exist,	and	one	of	the	most	favored	cognitive	screening	tools	to	identify	PD-MCI	is	 the	Montreal	 Cognitive	Assessment	 (MoCA)	 [9].	However,	 the	MoCA	was	 originally	 designed	 as	 a	global	cognitive	assessment	to	detect	mild	cognitive	impairment	in	Alzheimer’s	disease	(AD).	There	are	studies	validating	the	MoCA	in	PD,	showing	a	clear	benefit	of	the	MoCA	for	detecting	PD-MCI	and	PDD	compared	 to	 the	Mini-Mental	 State	Examination	 (MMSE)	 [10-12].	 Compared	 to	 the	 initial	 validation	study	 in	AD,	 some	studies	with	PD	cohorts	 suggest	a	different	cut-off	 score	 for	 the	MoCA	 to	classify	cognitive	impairment	[11,10].	Though,	there	are	also	limitations	to	the	MoCA	regarding	its	application	to	a	PD	patient	group.	Fengler	et	al.	[13]	criticized	that	the	scoring	system	of	the	MoCA	does	not	consider	subtest	discriminant	power	to	distinguish	between	cognitive	impairment	and	no	cognitive	impairment	in	PD.	Considering	the	 importance	of	executive	dysfunctions	 in	PD,	 it	should	be	noted	that	 the	three	subtests	of	 visuospatial	 and	executive	 functions	only	 represent	30%	of	 the	 total	 score,	 compared	 to	orientation,	 which	 represents	 20%.	 However,	 it	 is	 known	 that	 executive	 functions	 are	 the	 most	prominent	and	often	the	first	cognitive	deficits	noticeable	in	PD	[14].	Therefore,	it	is	a	crucial	domain	to	diagnose	cognitive	impairment	in	PD.	Fengler	et	al.	[13]	developed	a	weighting	system	for	the	MoCA	subtests	by	addressing	the	diagnostic	accuracy	of	each	subtest	for	cognitive	impairment	in	PD	(PD-MCI	and	PDD)	with	a	receiver	operating	characteristic	(ROC)	analysis.	By	calculating	the	area	under	the	curve	(AUC)	for	each	subtest,	the	authors	weighted	visuospatial	and	executive	functions	higher	than	before.	For	example,	the	Trail	Making	Test	received	only	one	point	on	the	original	MoCA	and	now	four	points,	and	word	list	learning	performance	is	scored	with	three	points,	whereas	it	did	not	receive	any	points	on	the	original	MoCA.	In	contrast,	orientations’	weight	was	reduced	from	six	points	to	one	point	out	of	30	compared	 to	 the	original	version.	When	 testing	 their	weighted	scoring	system	 in	a	 small	PD	patient	group,	they	found	that	the	sensitivity	of	the	weighted	MoCA	was	higher	than	the	original	version,	without	loss	of	specificity	for	discriminating	PD	patients	with	any	cognitive	impairment	from	those	with	normal	cognition.		
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Based	on	their	low	sample	size,	which	included	patients	with	PDD,	it	is	still	unclear	whether	this	novel	weighted	MoCA	score	discriminates	between	PD-MCI	and	PD	patients	with	no	cognitive	 impairment.	Thus,	the	aim	of	this	present	study	was	to	validate	the	weighted	MoCA	scoring	algorithm	in	a	large	non-demented	PD	cohort.	We	hypothesized	that	the	weighted	MoCA	score	would	have	a	better	diagnostic	accuracy	 for	 PD-MCI	 and	 would	 be	 more	 highly	 correlated	 to	 results	 in	 other	 neuropsychological	assessments	than	the	unweighted	original	version.				
Methods		
Participants		Two	hundred	and	forty-one	PD	patients	were	recruited	from	the	outpatient	clinic	of	the	University	of	Tübingen	 as	 part	 of	 the	 “Amyloid-Beta	 in	 cerebrospinal	 spinal	 fluid	 as	 a	 risk	 factor	 for	 cognitive	dysfunction	in	Parkinson’s	Disease”	(ABC-PD)	study.	Patients	between	50	and	85	years	of	age	diagnosed	with	PD	according	to	the	United	Kingdom	PD	Brain	Bank	criteria	[15],	who	agreed	to	a	lumbar	puncture,	were	recruited.	Exclusion	criteria	for	the	ABC-PD	study	participation	were:	diagnosis	of	PDD	according	to	 Level	 II	 consensus	 guidelines	 [16],	 severe	 concomitant	 diseases	 affecting	 patients’	 judgement	 for	informed	consent,	and	history	of	substance	abuse	(except	for	nicotine).	In	addition,	patients	with	deep	brain	 stimulation	 (DBS)	 were	 excluded.	 In	 the	 present	 study,	 only	 patients	 with	 a	 complete	 MoCA	assessment	were	 analyzed;	 data	 of	 12	 (5%)	 patients	with	 a	missing	MoCA	were	 excluded	 from	 the	analysis.	Furthermore,	7	(2.9%)	patients	with	concomitant	neurological	diseases	(e.g.	history	of	stroke,	epilepsy)	and	23	(9.5%)	PD	patients	with	a	moderate	or	severe	depression	as	defined	by	a	cut-off	≥	20	points	on	the	Beck	Depression	Inventory	II	(BDI-II)	[17],	were	also	excluded	to	ensure	that	cognitive	dysfunctions	were	primarily	caused	by	PD	[18,19].	In	total,	202	PD	patients	were	included	in	the	present	data	analysis.	The	study	was	approved	by	the	local	ethics	committee	of	the	University	of	Tübingen.	All	patients	gave	written	informed	consent.				
Assessments		Demographics	and	medication	intake	to	express	the	levodopa	equivalent	daily	dose	(LEDD)	[20]	were	collected.	The	Unified	Parkinson’s	Disease	Rating	Scale	part	 III	 (UPDRS-III)	and	 the	Hoehn	and	Yahr	Stage	(H&Y)	were	used	to	rate	severity	of	PD-related	motor	symptoms.	The	Beck	Depression	Inventory	II	was	applied	to	screen	for	signs	of	depression	[17].		The	 MoCA	 is	 a	 cognitive	 screening	 tool	 developed	 to	 define	 mild	 cognitive	 impairment,	 assessing	executive	and	visuospatial	functions,	abstraction,	naming,	orientation,	attention,	language,	and	memory	
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performance.	 In	 this	 study,	 the	 original	 subtest	 scoring	 of	 the	MoCA	 [9],	 as	well	 as	 a	 new	weighted	scoring	 algorithm,	 was	 calculated	 [13].	 The	 new	 scoring	 algorithm	 evaluates	 each	 domain	 by	 its	individual	 discriminant	 power	 for	 PD	 with	 cognitive	 impairment.	 A	 maximum	 of	 30	 points	 can	 be	reached	in	both	versions.	The	MoCA	was	conducted	before	the	neuropsychological	test	battery	on	the	same	day.		To	 distinguish	 between	 patients	 with	 and	 without	 cognitive	 impairment,	 a	 comprehensive	neuropsychological	battery	was	applied.	Executive	functions	were	assessed	by	semantic	and	phonemic	fluency,	 and	 the	Trail	Making	Test	 part	B	 of	 the	 Consortium	 to	Establish	 a	Registry	 for	Alzheimer’s	disease	–	Plus	(CERAD-Plus)	[21].	Memory	performance	was	tested	using	the	following	three	CERAD-Plus	subtests:	word	list	learning,	word	list	recall,	and	praxis	recall.	Scores	of	the	Praxis	(CERAD-Plus)	and	the	Fragmented	Words	test	(Leistungsprüfsystem,	LPS	50+)	[22]	constituted	visuospatial	abilities.	Attention	was	assessed	with	the	Digit-Number	and	Letter-Number-Sequencing	subtest	of	the	Wechsler	Adult	Intelligence	Scale	(WIE)	[23].	The	Boston	Naming	Test	(CERAD-Plus)	and	the	Similarities	subtest	of	the	WIE	evaluated	language	function.	The	CERAD-Plus	corrects	for	education,	age,	and	gender,	while	the	LPS	50+	and	WIE	are	normed	for	age.		Diagnosis	of	PD-MCI	was	made	according	to	the	MDS	Level-II	criteria	[24].	Impairment	in	at	least	two	neuropsychological	tests	(≤	1.5	standard	deviations	(SD)	from	the	population	mean	reported	in	the	test	handbooks)	either	in	one	or	two	cognitive	domains	was	required	for	diagnosis	of	PD-MCI.	PD	patients	who	 did	 not	 meet	 these	 criteria	 were	 classified	 as	 having	 normal	 cognitive	 function	 (PD-NC).	Additionally,	we	classified	PD-MCI	with	a	cut-off	of	1	SD	and	2	SD	equal	or	below	the	population	mean	to	classify	cognitive	impairment	in	an	early	and	advanced	stage	in	PD.			
Statistical	Analysis		Study	data	were	collected	and	managed	using	REDCap	electronic	data	capture	[25].	Data	analysis	was	performed	by	use	of	the	IBM	SPSS	Statistics	version	23	and	the	statistical	software	MedCalc	(Version	17.1,	MedCalc	Software).	Figures	were	created	using	Microsoft	Excel	2013.	Except	 for	 the	UPDRS-III	score,	data	were	not	normally	distributed,	as	verified	by	the	Shapiro-Wilk	test.	Therefore,	the	Pearson	chi-squared	test	(gender	and	Hoehn	&	Yahr	stage),	independent-samples	t-test	(UPDRS-III	score)	and	the	 Mann-Whitney-U-test	 (all	 other	 variables	 including	 MoCA)	 were	 conducted	 for	 between-group	comparisons	of	PD-NC	and	PD-MCI.	The	Wilcoxon-Test	was	used	to	compare	the	original	and	weighted	MoCA	scores	in	all	PD	patients	and	cognitive	subgroups.	We	also	calculated	the	score	difference	of	the	two	MoCA	versions	by	subtracting	the	weighted	MoCA	scores	from	the	original	MoCA	scores.	With	the	Mann-Whitney-U-test	we	compared	the	MoCA	score	difference	between	PD-NC	and	PD-MCI.			
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A	ROC	analysis	was	conducted	to	validate	the	diagnostic	accuracy	of	the	original	and	weighted	MoCA	by	means	of	sensitivity	and	specificity.	The	Youden’s	index	was	calculated	to	define	the	optimal	cut-off	for	the	original	and	weighted	MoCA	for	PD-MCI.	All	 group	 comparisons	 and	 ROC	 analyses	were	 applied	 independently	 to	 each	 of	 the	 three	 PD-MCI	classifications	by	using	a	cut-off	of	either	≤	1	SD,	1.5	SD,	or	2	SD	below	the	appropriate	norms.	The	Spearman	correlation	coefficient	(rs)	was	used	to	evaluate	the	strength	of	the	association	between	the	two	MoCA	scores.	To	identify	the	congruent	validity	of	both	MoCA	scores,	the	scores	were	correlated	with	the	average	z-values	of	all	neuropsychological	tests	assigned	to	their	respective	cognitive	domain.				
Results		All	202	PD	patients	were	classified	according	to	the	three	differing	PD-MCI	classification	approaches.	The	1	SD	cut-off	led	to	74	PD-NC	(36.6%)	and	128	(63.4%)	PD-MCI	patients,	the	1.5	SD	cut-off	to	125	(61.9%)	PD-NC	and	77	(38.1%)	PD-MCI	patients,	and	the	2	SD	cut-off	to	162	(80.2%)	PD-NC	and	40	(19.2%)	PD-MCI	patients.	In	general,	the	PD-MCI	patients	suffered	from	more	severe	motor	problems	(see	Table	1	for	details)	and	showed	significantly	 lower	test	performances	on	all	neuropsychological	tests	and	cognitive	domains	than	PD-NC	patients	(p	≤	0.001)	(for	details	we	refer	to	Online	Resource	Table	1).	According	to	the	1,	1.5,	or	2	SD	cut-off,	93.8%,	93.5%,	and	95.0%	respectively,	of	all	PD-MCI	patients	were	classified	as	multi	domain	PD-MCI.		The	correlation	between	the	original	and	weighted	MoCA	score	was	high	(rs	=	0.89,	p	<	0.001).	In	the	total	PD	sample,	the	score	range	of	the	original	MoCA	varied	between	16	and	30	(Median,	Mdn	=	26)	points	and	on	the	weighted	MoCA	score	between	11	and	30	(Mdn	=	26)	points.			For	 all	 PD-MCI	 classifications	 in	 both	 the	 original	 and	weighted	MoCA	 scores,	 PD-MCI	 patients	 had	significantly	lower	values	than	the	PD-NC	group	(p	<	0.001).	In	the	PD-MCI	groups,	the	weighted	MoCA	had	significantly	lower	values	than	the	original	MoCA	across	all	classifications	(p	<	0.001)	(see	Figure	1	for	details).	In	the	PD-NC	patient	groups,	the	original	and	weighted	MoCA	did	not	differ	(1	SD:	p	=	0.06;	1.5	SD:	p	=	0.13),	except	for	the	2	SD	cut-off,	where	PD-NC	patients	showed	a	significantly	lower	MoCA	score	in	weighted	MoCA	compared	to	the	original	MoCA	(Mdn	=	27,	range:	14-30	vs.	27,	18-30,	p	=	0.005)	(see	Figure	1	 for	details).	 Comparing	 the	 score	difference	between	 the	original	 and	weighted	MoCA	revealed	significantly	higher	differences	for	PD-MCI	than	PD-NC	for	all	classifications	(1	SD:	Mdn:	1	vs.	0;	p	=	0.029;	1.5	SD:	1	vs.	0;	p	<0.001;	2	SD:	2	vs.	0;	p	<0.001).	Both	MoCA	versions	were	moderately	associated	with	each	cognitive	domain	(0.38	≤	rs	≤	0.52)	and	did	not	statistically	differ	in	the	strengths	of	association	to	each	cognitive	domain	(p	>	0.05)	(see	Table	2	for	details).		AUC	values	of	the	original	(0.76,	95%	confidence	interval,	CI:	0.70	–	0.82)	and	weighted	(0.81,	CI:	0.75	–	0.86)	version	varied	significantly	in	the	2	SD	classification	(p	=	0.044),	but	not	for	the	classification	of	
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PD-MCI	according	 to	 the	1	SD	 (p	 =	0.32)	and	1.5	SD	cut-offs	 (p	=	0.15).	The	ROC	analysis	 identified	different	cut-offs	maximizing	both	sensitivity	and	specificity	for	the	original	and	weighted	MoCA	for	the	diagnosis	of	PD-MCI	(Table	3).	For	both	MoCA	versions,	an	optimal	cut-off	of	26	was	revealed	using	the	1	 SD	 cut-off	 to	define	PD-MCI.	 Sensitivity	 showed	a	 tendency	 to	 increase	 from	57.8%	 to	64.1%	and	specificity	decreased	slightly	from	86.5%	to	77.0%	because	of	the	weighted	MoCA,	leading	to	a	slightly	increased	positive	predictive	value	(PPV)	from	54.2%	to	55.3%	and	decreased	negative	predictive	value	(NPV)	from	88.1%	to	82.8%	compared	to	the	original	version.	With	the	1.5	SD	cut-off	for	defining	PD-MCI,	an	optimal	cut-off	of	27	was	revealed	for	the	original	MoCA	and	26	for	the	weighted	version.	Here,	due	to	the	weighted	MoCA,	sensitivity	slightly	decreased	from	77.9%	to	75.32%	and	specificity	showed	a	tendency	to	increase	from	60.8%	to	67.2%	compared	to	original	MoCA.	The	PPV	remained	stable	(81.7	vs.	81.6%)	and	the	NPV	increased	from	55.0%	to	58.6%	with	the	weighted	MoCA.	By	using	a	2	SD	cut-off	 to	 classify	 PD-MCI,	 an	 optimal	 cut-off	 of	 26	was	 revealed	 for	 the	 original	MoCA	 and	 24	 for	 the	weighted	version.	Sensitivity	slightly	increased	from	70.0%	to	72.5%	due	to	the	weighted	MoCA	and	specificity	 also	 increased	 from	 65.4%	 to	 79.0%	 compared	 to	 original	 MoCA.	 Therefore,	 the	 PPV	increased	from	89.8%	to	92.1%	and	the	NPV	increased	from	33.3%	to	46.0%.			
Discussion		The	purpose	of	 the	present	 study	was	 to	 validate	 a	novel	weighted	MoCA	 scoring	 algorithm	 for	 the	diagnosis	of	PD-MCI	in	a	large	sample	of	non-demented	PD	patients.			The	main	 results	 are	 that	 (i)	 both	 the	 original	 and	 the	weighted	MoCA	 scores	 differed	 significantly	between	 PD-NC	 and	 PD-MCI	 patients,	 (ii)	 within	 PD-MCI	 patients,	 the	weighted	MoCA	 scores	were	significantly	lower	than	those	for	the	original	MoCA,	(iii)	diagnostic	accuracy	of	the	two	MoCA	versions	was	found	to	be	highly	dependent	on	the	cut-off	score	used	to	classify	PD-MCI,	and	(iv)	the	association	of	both	MoCA	scores	to	the	neuropsychological	domain	scores	was	comparable.		In	 the	 present	 study	 the	 cut-offs	 for	 the	 original	 and	 weighted	 MoCA	 score	 were	 determined	 by	maximizing	the	ratio	of	sensitivity	and	specificity	(defined	by	the	Youden’s	index).	For	each	version,	the	optimal	cut-off	was	analysed	to	ensure	the	highest	diagnostic	accuracy	for	PD-MCI	of	each	MoCA	score.	With	a	cut-off	≤	1.5	SD	to	define	PD-MCI,	we	found	an	optimal	cut-off	of	26	for	the	weighted	MoCA	and	27	for	the	original	MoCA.	Therefore,	our	proposed	cut-off	for	the	original	MoCA	version	is	slightly	higher	than	that	of	Nasreddine	et	al.	[9],	who	recommended	a	score	of	26.	However,	their	suggestion	applies	to	AD	 patients	 and	 is	 therefore	 not	 necessarily	 applicable	 to	 PD	 patients.	 Other	 studies	 have	 already	discussed	 an	 optimal	 cut-off	 in	 PD.	 Using	 a	 1.5	 SD	 cut-off	 to	 identify	 patients	 with	 any	 cognitive	impairment,	Hoops	et	al.	[11]	found	a	cut-off	score	of	25,	which	is	two	points	lower	than	ours.	However,	the	 cut-off	 was	 not	 only	 defined	 for	 PD-MCI	 but	 also	 PDD	 patients	 (summarized	 as	 any	 cognitive	impairment),	which	might	explain	the	lowered	cut-off	score.	Dalrymple-Alford	et	al.	[10],	suggest	a	cut-
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off	at	26	points	for	PD-MCI	(also	defined	by	a	1.5	SD	cut-off).	Our	results	for	the	original	MoCA	do	not	support	these	findings,	as	our	results	suggest	a	slightly	higher	MoCA	cut-off	at	27	points.	Defining	PD-MCI	in	our	sample	with	a	1	SD	cut-off,	revealed	optimal	cut-off	scores	of	26	for	both	the	original	and	weighted	MoCA.	With	 a	 2	 SD	 cut-off,	 for	 the	 original	MoCA	 a	 cut-off	 26	was	 identified,	 and	 for	 the	weighted	MoCA	a	distinctly	lowered	cut-off	of	24.	However,	there	are	no	studies	confirming	this	cut-off	for	 early	 and	 later	 stages	 of	 PD-MCI.	 More	 studies	 in	 large	 PD	 samples	 are	 needed	 to	 confirm	 the	diagnostic	cut-off	of	the	MoCA.		With	a	1.5	SD	cut-off	for	PD-MCI,	we	did	not	find	a	significant	difference	between	the	AUC	of	the	ROC	analysis	for	the	two	MoCA	versions.	Due	to	the	weighted	MoCA,	sensitivity	was	slightly	lowered	by	2.6%	and	 specificity	 increased	 by	 6.4	 %	 compared	 to	 the	 original	 MoCA.	 Compared	 to	 the	 initial	 study,	sensitivity	 and	 specificity	 are	 altogether	 lowered	 for	 the	 weighted	 MoCA.	 We	 also	 did	 not	 find	 a	significant	difference	of	 the	AUC	with	a	1	SD	cut-off.	This	does	not	 support	 the	notion	of	a	 superior	discriminant	power	of	the	weighted	MoCA	score.	However,	with	a	2	SD	cut-off	 to	define	PD-MCI,	 the	weighted	MoCA	seems	to	be	advantageous	to	the	original	MoCA.	The	AUC	level	of	the	weighted	MoCA	was	significantly	higher	than	the	AUC	of	the	original	version	(AUC:	0.81	vs.	0.76;	p	=	0.044),	which	led	to	an	increased	sensitivity	(70.0%	vs.	72.5%)	and	specificity	(65.4	vs.	79.0%).	This	improvement	is	also	represented	by	a	high	PPV	of	92.1%	and	moderate	NPV	of	46.3%.	This	was	an	unexpected	finding	as	the	weighted	MoCA	places	a	higher	priority	on	executive	function,	which	is	considered	to	be	highly	frequent	in	early	stages	of	PD-MCI.	However,	the	weighted	MoCA	takes	visuospatial	deficits	more	into	account.	Lower	visuospatial	cognitive	function	has	been	found	to	be	associated	to	a	faster	cognitive	decline	and	progression	to	PDD.			The	fact	that	patients	with	PD-MCI	not	only	scored	significantly	lower	on	the	weighted	than	the	original	MoCA	 version,	 but	 that	 the	 score	 differences	 between	 the	 original	 and	 weighted	 version	 were	substantially	 larger	 in	 PD-MCI	 than	 PD-NC,	 further	 indicates	 that	 the	weighted	MoCA	 score	 reflects	cognitive	impairment	associated	to	PD-MCI	to	a	greater	degree.	This	effect	was	found	to	be	independent	of	the	applied	PD-MCI	classification	cut-off.	Cognitive	impairment	in	PD	is	highly	heterogeneous	and	its	severity	might	reflect	a	continuum	rather	than	a	sudden	onset	of	dysfunction.	So	far,	progression	of	the	cognitive	decline	is	only	partly	understood;	while	some	patients	develop	PDD	within	a	short	time	period,	others	 remain	 stable	 or	 even	 return	 to	 a	 non-impaired	 level	 [26,27,2].	However,	 no	 reliable,	 purely	cognitive	predictor,	has	been	identified	to	encircle	a	risk	group	for	PDD	among	PD-MCI.	In	summary,	our	findings	 show	 that	 the	weighted	MoCA	detects	 cognitive	dysfunction	 in	PD-MCI	 to	a	greater	degree,	especially	in	more	advanced	stages	of	cognitive	impairment.	It	is	possible	that	PD-MCI	patients	scoring	lower	on	the	weighted	MoCA	version	might	be	at	higher	risk	for	conversion	to	PDD	than	PD-MCI	patients	scoring	higher	on	the	weighted	MoCA.	In	the	PD-NC	group,	the	weighted	MoCA	did	not	differ	significantly	from	the	original	for	the	1	SD	and	1.5	SD	cut-off	for	PD-MCI.	However,	at	a	2	SD	cut-off,	PD-NC	patients	scored	significantly	lower	in	the	weighted	MoCA	than	in	the	original	MoCA.	By	application	of	this	cut-off	we	suggest	that	there	are	at	least	some	patients	with	cognitive	impairment	at	a	mild	stage	in	the	PD-NC	group.	In	our	sample,	deficits	of	those	persons	could	be	better	detected	by	the	weighted	than	the	original	
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MoCA.	To	 further	 investigate	 the	notion	of	 a	possible	 risk	 group,	 longitudinal	 studies	 are	needed	 to	monitor	patients’	disease	progression	in	large	PD	samples.	In	our	study,	the	low	MoCA	scores	pose	the	question	of	whether	those	patients	might	already	have	PDD.	However,	patients	did	not	show	any	signs	of	activity	of	daily	living	dysfunctions,	which	is	the	core	criteria	for	PDD	diagnosis.		Correlations	between	both	MoCA	versions	and	each	cognitive	domain	also	ranged	at	a	moderate	level	and	did	not	differ	significantly,	indicating	that	both	versions	reflect	cognitive	domains	well.			As	a	limitation,	the	present	study	did	not	include	patients	with	PDD;	therefore,	we	do	not	know	whether	we	 could	 not	 replicate	 the	 results	 from	 the	 validation	 study	 due	 to	 these	missing	 PDD	 patients,	 or	because	of	a	possible	invalidity	of	the	scoring	algorithm.	Another	important	difference	compared	to	the	study	 of	 Fengler	 et	 al.	 [13]	 is	 the	 exclusion	 of	 patients	with	moderate	 or	 severe	 depression	 in	 our	analysis.	In	PD,	depression	is	very	common	[28]	and	it	is	well-known	that	occurrence	of	depression	has	a	negative	influence	on	cognitive	functions	[18].	Hence,	it	is	possible	that	the	development	of	the	new	weighted	scoring	algorithm	was,	at	least	partly,	affected	by	the	presence	and	severity	of	depression.	In	our	cohort,	cases	of	moderate	and	severe	depression	were	excluded	and	BDI-II	total	scores	did	not	differ	significantly	between	the	remaining	PD-NC	and	PD-MCI	patients.	Therefore,	we	concluded	that	cognitive	functions	could	not	be	ascribed	to	severity	of	depression	in	our	sample.	Also	compared	to	the	 initial	study,	we	excluded	patients	with	DBS.	Cognitive	decline	after	DBS	surgery	in	PD	has	been	controversially	discussed	[29,30].	To	diminish	this	possible	cause	of	cognitive	impairment	we	did	not	include	patients	with	DBS.		It	is	important	to	mention	that	differences	in	the	data	between	Fengler	et	al.	[13]	and	our	study	might	result	 from	differences	 in	 the	 neuropsychological	 test	 assessments	 utilized	 to	 classify	 PD-MCI.	 Both	studies	used	the	CERAD-Plus	test	battery	to	assess	memory,	executive	functions,	and,	to	some	extent,	visuospatial	and	language	impairment.	However,	some	tests	differ,	especially	in	the	attention	domain.	For	more	details	see	Online	Resource	Table	2.	This	might	 lead	 to	varying	 interpretation	of	cognitive	impairment	 in	 patients,	 even	 though	both	 studies	 used	 the	MDS	Level	 II	 criteria	 to	 identify	PD-MCI	patients.	Another	noteworthy	difference	to	the	study	by	Fengler	and	colleagues	(2017)	is	that	they	used	a	1.28	SD	cut-off	for	the	CERAD	subtests	as	suggested	by	the	test	manual	and	a	percentile	rank	for	the	two	tests	not	related	to	the	CERAD	test	battery.	In	our	study	the	diagnostic	value	of	different	cut-offs	(1,	1.5	and	2	SD)	for	PD-MCI	were	compared,	therefore	we	cannot	compare	our	study	and	the	initial	study	entirely.			All	neuropsychological	tests	applied	were	standardized,	however	subtests	of	the	WIE	and	LPS	50+	only	correct	for	age	whereas	the	CERAD-Plus	additionally	corrects	for	education	and	gender.	Therefore,	we	cannot	 rule	 out	 that	 education	 and	 gender	 status	 may	 have,	 at	 least	 partly,	 affected	 our	 PD-MCI	classification.	As	 the	proportion	of	males	 in	our	PD-NC	and	PD-MCI	groups	was	comparable	and	 the	educational	level	did	not	differ	statistically	between	groups,	we	conclude	that	between	groups	effect	of	the	MoCA	can	be	 interpreted	 in	our	 sample.	 Furthermore,	 our	 cohort	did	differ	 in	motor	 symptoms	
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which	might	partly	influence	some	test	results.	There	is	also	some	evidence	regarding	the	influence	of	dopaminergic	therapy	on	cognitive	test	performances	[26].	Normative	values,	especially	for	the	MoCA,	that	take	such	confounders	into	account	would	be	valuable	for	the	assessment	of	cognitive	impairment	in	PD.	This	also	applies	to	the	use	of	the	MoCA	in	clinical	routine	as	a	screening	tool	for	a	first	impression	of	patients’	cognitive	status.	Further	comprehensive,	diagnostic	Level	II	testing	can	then	be	applied	after	the	 noticeable	 MoCA	 score.	 In	 our	 study,	 the	 MoCA	 was	 conducted	 separately	 before	 the	neuropsychological	 tests.	 However,	 we	 cannot	 exclude	 the	 influence	 of	 variabilities	 concerning	 the	individual	investigators	or	the	time	during	the	day	of	the	assessment	on	test	performances.			In	summary,	we	conclude	that	the	weighted	MoCA	has	an	advantage	for	detecting	cognitive	impairment	in	more	 advanced	 stages	 over	 the	 original	 version.	 However,	 we	 can	 only	 confirm	 a	 better	 overall	discriminant	power	due	to	the	novel	scoring	algorithm	for	PD-MCI	patients	classified	with	a	2	SD	cut-off,	leading	to	a	high	PPV	and	increased	NPV	compared	to	the	original	version.	Therefore,	the	application	of	 the	weighted	MoCA	might	have	a	higher	potential	 to	 encircle	 those	PD	patients	 at	 risk	 for	 future	conversion	to	PDD,	which	needs	to	be	verified	with	longitudinal	studies.				
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	Figure	1		 Clustered	boxplots	for	original	and	weighted	Montreal	Cognitive	Assessment	(MoCA)	total	scores	for	both	Parkinson’s	disease	patients.	Divided	by	the	three	classification	cut-offs	with	different	standard	deviations	(SD).	Part	a)	refers	 to	 the	PD-NC	and	part	b)	 to	 the	PD-MCI	patient	group	with	no	cognitive	impairment	(PD-NC).	*	referring	to	a	significant	difference	with	p	<	0.01.																Table	1	 Characteristics	of	Parkinson’s	disease	patients	with	normal	cognition	(PD-NC)	and	mild	cognitive	impairment	(PD-MCI)	
	 	 Total	Sample	 PD-NC	 PD-MCI	 p-value	Number	 202	 117	 85	 	Male	n	(%)	 133	(65.8)	 78	(66.7)	 55	(64.7)	 0.77	Age		 66.1	(48.1-82.2)	 66.0	(48.1-79.9)	 66.7	(50.6-82.2)	 0.12	Education	Years		 13	(8-21)	 13	(8-21)	 12	(8-21)	 0.08	Age	at	Onset		 60.8	(36.4-79.5)	 60.4	(36.4-77.6)	 61.2	(45.5-79.5)	 0.28	Disease	Duration	Years		 4.1	(0-18.4)	 3.8	(0.1-18.4)	 4.8	(0-15.4)	 0.39	LEDD		 480.0	(0-1574.0)	 436.8	(0-1574.0)	 510.0	(0-1380.0)	 0.036*	UPDRS-III	Mean	(SD)	 25.4	(10.7)	 23.7	(10.44)	 27.7	(10.68)	 0.009*	H	&	Y	n	(%)	 	 	 	 0.039*	1	 28	(13.9)	 20	(17.1)	 8	(9.4)	 	2	 112	(55.4)	 70	(59.8)	 42	(49.4)	 	3	 60	(29.7)	 26	(22.2)	 34	(40.0)	 	4	 2	(1.0)	 1	(0.9)	 1	(1.2)	 	BDI-II	Score		 7	(0-19)	 6	(0-19)	 7	(0-19)	 0.22	Weighted	MoCA	Score	 26	(11-30)	 27	(14-30)	 23	(11-30)	 <0.001*	Original	MoCA	Score	 26	(16-30)	 27	(20-30)	 25	(16-30)	 <0.001*	
	
Note.	If	not	other	indication,	values	are	given	as	Median	(range);	LEDD	=	Levodopa	Daily	Dose;	UPDRS-III	 =	 Unified	 Parkinson’s	 Disease	 Raring	 Scale	 part	 III;	 H	 &	 Y	 =	 Hoehn	&	 Yahr	 stage,	 BDI-II	 =	 Beck	Depression	Inventory	II;	MoCA	=	Montreal	Cognitive	Assessment	
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Table	2	 Spearman	 rank	 correlations	 coefficients	 (rs)	 between	 each	 of	 the	 two	 MoCA	 total	 and	cognitive	 domain	 scores	 including	 statistical	 comparison	 between	 these	 two	 correlation	coefficients.	
	 r	s	 	Cognitive	Domain	Score		(z-value)	 Original	MoCA	total	score	 Weighted	MoCA	total	score	 p-value	Executive	functions	 0.42	 0.44	 0.20	Memory	 0.41	 0.41	 0.50	Visuospatial	functions	 0.38	 0.42	 0.09	Attention	 0.50	 0.50	 0.50	Language	 0.48	 0.43	 0.05	
	Note.	*	significant	difference	with	p<0.05		
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Abstract		
	INTRODUCTION:	 Evidence	 suggests	 urinary	 urgency	 is	 associated	 with	 cognitive	 impairment	 in	 a	subtype	 of	 Parkinson’s	 disease	 (PD)	 patients.	 This	 study	 investigates	 if	 cognitive	 impairment	independently	predicts	the	presence	of	urinary	dysfunction.			METHODS:	We	report	data	of	189	idiopathic	PD	patients,	excluding	those	with	concomitant	diseases	or	medication	 interacting	 with	 bladder	 function.	 A	 standardized	 questionnaire	 was	 used	 to	 define	presence	of	urinary	urgency.	All	patients	underwent	a	comprehensive	motor,	cognitive	non-motor	and	health-related	 quality	 of	 life	 (HRQoL)	 assessment.	 Multivariable	 linear	 regression	 analysis	 was	performed	 to	 identify	 independent	 predictors	 of	 urinary	 urgency	 (PD-UU),	 which	 were	 applied	 as	discriminant	features	to	estimate	their	individual	contribution	to	the	phenotype	of	PD-UU	group.		RESULTS:	Of	189	PD	patients,	105	(60.8%)	reported	PD-UU.	Among	cognitive	domains,	only	executive	function	(EF)	(p	=	.04)	was	associated	with	PD-UU.	In	a	second	model,	scores	of	the	Montreal	Cognitive	Assessment	(MoCA)	significantly	differentiated	between	study	groups	(p	=	.007)	and	with	non-motor	symptom	(NMS)	burden	(p	<	.001).	The	third	model	consisted	of	reports	of	HRQoL,	of	which	stigma	was	the	only	subscale	of	the	Parkinson’s	Disease	Questionnaire	(PDQ-39)	differentiating	between	patients	with	and	without	PD-UU	(p	=	.02).	Linear	discriminant	analysis	provided	evidence	that	the	combination	of	EF,	NMS	impairment,	and	stigma	differentiated	between	groups	with	72.4%	accuracy.			CONCLUSION:	In	our	large,	non-demented	PD	cohort,	urinary	urgency	was	associated	with	executive	dysfunction,	 supporting	 a	 possible	 causative	 link	 between	 both	 symptoms.	 A	 combination	 of	neuropsychological	 and	 non-motor	 aspects	 identified	 patients	with	 PD-UU	with	 high	 discriminative	accuracy.		 	
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Introduction	
	Urinary	 urgency	 is	 a	 common	 non-motor	 symptom	 in	 Parkinson’s	 disease	 (PD)	 [1-3].	 Presence	 of	urinary	urgency	 in	PD	 (PD-UU)	 lowers	patients’	health-related	quality	of	 life	 (HRQoL)	 [4,	5]	 and	 its	frequency	is	higher	as	among	older	healthy	individuals	[6,	7].	To	date,	no	effective	treatment	of	PD-UU	exists.	The	 influence	of	dopaminergic	medication	 is	not	predictable	 [8]	and	standard	anticholinergic	medication	 should	 be	 avoided,	 for	 its	 negative	 impact	 on	 cognition	 [9].	 Therefore,	 novel	 treatment	approaches	are	necessary.			Bladder	dysfunction	has	been	linked	to	a	variety	of	clinical	PD-related	symptoms,	including	cognition	[10-12].	Contrary,	recent	study	found	no	association	between	PD-UU	and	cognitive	impairment	[12].	In	this	 study,	 applied	 cognitive	 screening	 assessment,	 did	 not	 provide	 insight	 into	 domain	 specific	characterization	of	cognitive	functions.	In	vascular	dementia,	as	well	as	in	healthy	elderly	adults,	the	loss	of	EF	has	been	reported	to	be	related	to	urinary	incontinence	[13,	14].	The	impairment	in	EF	is	a	common	feature	in	PD	[15],	which	raises	the	question	if	these	specific	function	associates	with	PD-UU	in	a	subtype	of	PD	patients,	independent	from	the	presence	of	dementia.			Our	primary	aim	was	to	verify	the	role	of	domain	specific	cognitive	impairment,	independent	from	the	effect	 of	 other	 symptoms,	 in	 the	 occurrence	 of	 PD-UU	 in	 a	 large,	 non-demented	 PD	 sample.	 We	hypothesized	 that	 especially	EF	would	be	 associate	 to	 the	presence	of	 PD-UU.	Taking	 limitations	 of	previous	 studies	 into	 account,	 we	 excluded	 patients	 with	 intake	 of	 medication	 or	 presence	 of	concomitant	diseases	interacting	with	bladder	function.				
Methods	
	
Patients		As	a	part	of	the	ongoing	“Amyloid-beta	in	CSF	as	risk	factor	for	cognitive	dysfunction	in	PD	(ABC-PD)”	study,	 262	 PD	 patients	 diagnosed	 according	 to	 the	 United	 Kingdom	 Brain	 Bank	 criteria	 [16]	 were	recruited.	 Inclusion	 criteria	 of	 the	 ABC-PD	 study	 were	 age	 between	 50	 and	 85	 years,	 adequate	 or	corrected	hearing/visual	abilities,	German	as	mother	tongue,	no	history	of	substance	abuse	except	for	nicotine,	and	no	further	neurological	diseases	affecting	the	central	nervous	system.	As	a	premise	for	the	ABC-PD	study,	informant	consent	for	a	lumbar	puncture	was	mandatory.	All	patients	were	examined	during	the	“on”	state	after	taking	their	regular	optimized	dopaminergic	treatment.			
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For	 the	 data	 analysis	 reported	 here,	 73	 (27.9%)	PD	patients	were	 excluded	due	 to	 the	 presence	 of	concomitant	diseases	 affecting	bladder	 control	 (see	Figure	1	 for	details).	Therefore,	 data	of	189	PD	patients	were	included	into	the	final	analysis.	The	study	was	approved	by	the	local	ethics	committee.	All	patients	gave	written	informed	consent	for	study	participation.			
Classification	of	PD-UU	vs.	PD-NUU		Item	8	of	the	validated	Parkinson’s	Disease	Non-motor	Symptoms	Questionnaire	(PDNMS-Quest)	[17]	was	used	to	differentiate	between	PD	patients	with	(PD-UU,	score	=	1)	and	without	(PD-NUU,	score	=	0)	urinary	urgency.			
Demographics,	medication,	and	motor	symptoms		Demographics	and	a	full	drug	history,	including	the	total	daily	dose	of	all	dopaminomimetics	[expressed	by	 the	 levodopa	 equivalent	 daily	 dose	 (LEDD)]	 and	 the	 total	 daily	 dose	 of	 dopaminergic	 agonists	medication	(DAEDD)	were	obtained.	Since	medications	with	anticholinergic	effects	have	been	identified	as	a	risk	factor	for	cognitive	decline,	the	anticholinergic	risk	score	(ARS)	for	medication	with	additional	anticholinergic	properties	was	 calculated.	 Severity	 of	motor	 symptoms	was	 assessed	by	 the	Unified	Parkinson’s	Disease	Rating	Scale	(UPDRS)	part	III	and	the	Hoehn-Yahr	(H	&	Y)	scale,	while	falls	were	assessed	with	item	13	of	the	UPDRS	part	II.			
Neuropsychological	test	battery		To	assess	major	areas	of	cognitive	function,	a	standardized	neuropsychological	test	battery	was	applied.	The	 MoCA	 was	 used	 to	 screen	 for	 patients’	 global	 cognitive	 status.	 The	 Consortium	 to	 Establish	 a	Registry	 of	 Alzheimer’s	 Disease	 Plus	 (CERAD-PLUS)	 test	 battery	 and	 subtests	 of	 the	 Wechsler	Intelligence	 Test	 for	 adults	 (WIE)	 as	 well	 as	 the	 Performance	 Evaluation	 for	 Seniors	(Leistungsprüfsystem,	LPS-50+)	were	assigned	to	the	following	cognitive	domains:	EF	(CERAD-PLUS:	lexical	 and	phonemic	 fluency,	Trial	Making	Test	B);	Attention/working	memory	 (WIE:	Digit	 Symbol	Test,	Letter	Number	Sequencing	Task);	Memory	(CERAD-PLUS:	Word	List	Learning,	Word	List	Recall,	Word	 List	 Recognition,	 Praxis	 Recall);	 Visuo-constructive	 abilities	 (CERAD-PLUS:	 Praxis,	 LPS-50+:	Fragmented	Words)	and	Language	(CERAD-PLUS:	Boston	Naming	Test,	WIE:	Similarities).		For	all	subtests,	z-scores	were	computed,	corrected	for	age	(all),	gender	(CERAD-PLUS),	and	education	(CERAD-PLUS)	where	possible.	For	each	of	the	above-mentioned	cognitive	domains,	a	mean	z-score	was	calculated.	PD-related	mild	cognitive	impairment	(PD-MCI)	was	diagnosed	based	on	recommendations	by	the	Level	II	criteria	of	the	Movement	Disorder	Society	Task	Force	[18].		
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Further	non-motor	function	scales			Depressive	symptoms	were	assessed	with	the	Beck	Depression	Inventory-II	(BDI-II)	[19].	Total	HRQoL	was	assessed	using	the	Parkinson’s	Disease	Questionnaire	total	score	(PDQ-39)[20].	The	total	score	was	built	out	of	39	questions,	divided	into	8	domains:	Mobility	(10	items);	Activities	of	daily	living	(ADL,	6	items);	Emotional	well-being	(6	items);	Stigma	(4	items);	Social	support	(3	items);	Cognitions	(4	items);	Communication	(3	items);	and	Bodily	discomfort	(3	items).	Other	non-motor	symptoms	were	evaluated	by	 the	 German	 version	 of	 the	 PD	 Non-Motor	 Symptom	 Questionnaire	 (NMSQuest)	 [21].	 Moreover,	instrumental	ADL	(iADL)	were	measured	by	the	Functional	Activities	Questionnaire	(FAQ)	[22].			
Statistics		Data	were	collected	and	managed	using	REDCap	electronic	data	capture	tools	[23]	and	analyzed	using	SPSS	22	for	Windows	(SPSS	Inc,	Chicago,	IL,	USA).	Descriptive	values	are	presented	as	mean,	standard	deviation	(SD),	number,	and	percentage	(%).	Comparisons	between	groups	were	performed	using	chi-squared	and	student’s	t-tests,	as	appropriate	(Table	1).	To	analyze	the	possible	predictors	of	PD-UU,	a	linear	regression	analysis	with	group	status	(PD-UU	vs.	PD-NUU)	as	the	dependent	variable	was	applied,	controlling	for	potential	confounders	(disease	duration	and	LEDD).	To	test	the	link	between	motor,	non-motor,	 and	 cognitive	 symptoms	 and	 PD-UU,	 three	 independent	 regression	models	were	 conducted.	
Model	A	consisted	of	all	five	cognitive	domain	scores	in	addition	to	the	covariates.	In	model	B,	the	PDQ-39	summary	index,	NMS-Quest,	FAQ,	MoCA	total	score,	and	falls	incidence	(UPDRS-II)	were	considered	to	evaluate	the	association	between	cognition	and	PD-UU	among	other	symptoms.	Given	the	covariance	between	total	score	and	the	subscales	scores	of	the	PDQ-39,	we	created	model	C,	in	which	all	subscales	were	included	as	independent	variables.	Based	on	significant	results	from	the	linear	regression	models,	a	blockwise	discriminant	function	was	performed	to	confirm	if	the	identified	variables	contributed	to	the	classification	of	PD-UU.	Wilks’	lambda	was	used	to	test	significance	of	the	model	fit	for	prediction	of	PD-UU,	 and	 the	 Box-M	 test	 evaluated	 variance	 homogeneity	 between	 both	 groups.	 To	 validate	 the	results	of	the	blockwise	model,	a	stepwise	discriminant	function	was	calculated.	Results	are	presented	as	mean	and	95%	confidence	intervals.			
Data	Availability	Statement		Due	to	ethical	restrictions	imposed	by	the	Ethics	Committee	of	the	Medical	Faculty	of	the	University	of	Tuebingen	related	to	approved	patient	consent	procedure	and	protecting	patient	privacy,	all	relevant	data	should	be	requested	at	Dr.	Inga	Liepelt-Scarfone	or	Prof.	Dr.	Thomas	Gasser	directly	using	the	email	address	 inga.liepelt@uni-tuebingen.de	 or	 in	 case	 of	 unavailability	 thomas.gasser@uni-tuebingen.de.	The	Ethical	Committee	decided	how	data	of	this	particular	study	should	be	handled	by	the	researchers;	however,	the	Ethical	Committee	does	not	have	access	to	the	actual	data.		
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Results	
	An	overview	of	demographic	and	clinical	characteristics	of	all	189	PD	patients	 (93	males,	49.2%)	 is	reported	 in	 Table	 1.	 Mean	 age	 of	 all	 PD	 patients	 was	 64.7±	 7.9	 years,	 with	 115	 patients	 (60.8%)	reporting	PD-UU.	Patients	reporting	PD-UU	had	longer	disease	durations	(p	=	.02)	and	higher	LEDDs	(p	=	 .01)	 compared	 to	 PD-NUU.	 In	 contrast,	 the	 DAEDD	 (p	 =	 .37)	 and	 ARS	 (p	 =	 .35)	 scores	 did	 not	significantly	 differ	 between	 study	 groups.	 Frequency	 of	 patients	 with	 diagnosis	 of	 PD-MCI	 did	 not	statistically	differ	between	groups.			Regarding	 the	 linear	 regression,	 among	all	 cognitive	domains	 (model	A),	 PD-UU	patients	performed	worse	on	tests	assessing	EF	(p	=	.04),	but	not	on	other	domains	compared	to	PD-NUU.	In	model	B,	the	MoCA	score	(p	=	.007)	and	the	total	score	of	NMSQuest	(p	<	.001)	significantly	differentiated	between	study	groups,	whereas	the	FAQ,	PDQ-39	total	score,	and	falls	rate	did	not	statistically	contribute	to	the	prediction	of	PD-UU.	Values	of	the	Stigma	subscale	of	the	PDQ-39	(model	C)	were	lower	among	PD-UU	patients	compared	to	PD-NUU	(p	=	.02)	and	was	considered	as	the	only	subscale	associated	with	the	presence	of	urinary	urgency.	The	cofounders	did	not	reach	significance	level	in	any	of	the	regression	models.		To	predict	group	membership	of	PD-UU,	we	executed	a	discriminant	analysis.	Predictor	variables	were	the	z-score	of	 the	EF	domain,	MoCA	total	score,	NMSQuest	 total	score,	and	the	PDQ39-	Stigma	scale	score.	Based	on	 the	blockwise	model,	PD-UU	patients	were	classified	with	an	accuracy	of	72.4%	for	group	discrimination	and	69.9%	of	variance	explained	by	the	variables.	Box’s	M	(p	=	.78)	and	Wilks’	lambda	(λ	=	0.67,	χ²	=	57.5,	df	=	4,	p	<	.001)	confirmed	a	high	quality	of	model	fit	resulting	in	the	following	discriminant	function	(DF):	DF	=	(0.59	x	EF)	+	(0.31	x	NMSQuest)	+	(-0.65	x	PDQ-39	Stigma)	-	2.79;	(p	<	.001).	Due	to	its	low	discriminant	power,	the	MoCA	score	was	not	included	in	the	DF.	In	the	discriminant	model,	the	pooled	within-groups	correlations	between	discriminating	variables	and	standard	canonical	discriminant	function	built	the	following	hierarchy:	NMSQuest	score	differentiated	best	between	PD-UU	and	PD-NUU	(p	<	.001),	followed	by	EF	(p	=	.03)	and	PDQ-39	Stigma	(p	=	.02).	The	stepwise	analysis	confirmed	that	all	variables	together,	apart	from	the	MoCA,	contributed	significantly	(p	<	.001)	to	group	discrimination	of	PD-UU	and	PD-NUU.				
Discussion	
	We	here	present	results	of	a	study	 investigating	the	 link	between	urinary	dysfunction	and	cognitive	impairment	in	a	selected	cohort	of	PD	patients	controlled	for	the	intake	of	concomitant	medication	and	presence	of	 age-related	bladder	 symptoms.	Our	most	 important	 finding	 is	 the	prediction	of	 urinary	
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urgency	 with	 high	 accuracy,	 given	 the	 combination	 of	 non-motor	 symptom	 burden,	 executive	dysfunction,	and	self-perceived	stigma	in	PD.			During	the	course	of	the	disease,	non-motor	symptoms	start	to	predominate	the	clinical	picture,	which	are	often	more	troublesome	for	patients	than	the	motor	symptoms	[24].	Hence,	it	is	important	to	detect	the	casual	relation	of	the	non-motor	burden	to	develop	more	specific	adjuvant	therapy	forms.		Our	data	shows	that	cognitive	impairment,	especially	EF,	is	an	independent	predictor	of	PD-UU	among	other	motor	and	non-motor	symptoms.	Some	reports	suggest	an	interdependence	between	autonomic	and	cognitive	symptoms,	which	was	shown	for	orthostatic	hypotension	and	cognitive	worsening	[25].	However,	 the	 association	 between	 PD-UU	 and	 cognition	 is	 only	 sparsely	 investigate	 despite	 a	 high	prevalence	rate	of	urinary	urgency	in	some	forms	of	dementia	or	late	stages	of	PD	[26-29].	PD-UU	can	be	caused	by	the	neurodegenerative	processes	of	the	prefrontal	cortex	since	the	frontal	cortex-basal	ganglia	circuit	plays	a	prominent	role	not	only	in	modulating	EF	and	goal-directed	behavior	[30]	but	also	 in	 suppressing	 micturition	 [31].	 Neuroimaging	 studies	 identified	 that	 the	 prefrontal	 cortex	 is	activated	 during	 bladder	 filling	 [32]	 and	 that	 progressive	 neurodegenerative	 changes	 in	 PD	 cause	disruptions	of	these	patterns	[33,	34].	The	causality	of	connection	between	EF	and	PD-UU	should	be	considered	 as	 bidirectional,	 as	 executive	 impairment	 might	 prevent	 PD	 patients	 from	 planning	 or	inhibiting	physiological	processes	that	lead	to	PD-UU.	In	our	study,	60.8%	of	non-demented	PD	patients	reported	 urinary	 urgency.	 This	 finding	 demonstrates	 that	 PD-UU	 is	 not	 limited	 to	 a	 subgroup	 of	demented	 PD	 patients	 or	 PD-MCI,	 but	 can	 develop	 early	 and	 correlate	 with	 early	 cognitive	deteriorations.	 The	 rate	 of	 patients	 with	 and	 without	 PD-MCI	 did	 not	 differ	 in	 our	 sample,	 which	emphasizes	that	cognitive	impairment	per	se	does	not	lead	to	onset	of	PD-UU.	Rather,	our	data	suggests	that	a	specific	cognitive	function	is	associated	with	the	presence	and	severity	of	PD-UU,	at	 least	 in	a	subtype	of	PD	patients.			In	our	study,	we	used	a	comprehensive	neuropsychological	battery,	including	tests	for	the	assessment	of	cognitive	domains.	This	approach	might	have	allowed	us	to	detect	prefrontal	cognitive	changes	that	other	 studies	 could	 not	 observe	 [12].	 Performance	 in	 the	MoCA	 did	 distinguish	 between	 our	 study	groups,	 however	 it	 did	 not	 independently	 contribute	 to	 classification	 of	 PD-UU	 in	 a	 discriminant	function	analysis.	The	MoCA	is	a	global	cognitive	assessment	with	a	lower	sensitivity	for	single	cognitive	domains	and	the	substantial	overlap	with	the	assessed	EF	tests	might	have	weakened	its	discriminative	role	in	further	analysis.	Contrary	to	our	findings,	in	the	PRIAMO	cohort,	no	association	between	urinary	dysfunction	and	the	global	cognitive	assessment,	measured	by	Mini-Mental	State	Examination	(MMSE),	independently	from	the	presence	and	severity	of	other	non-motor	symptoms,	could	be	identified	[12].	Further	studies	are	necessary	to	specify	the	distinctive	mechanism	of	executive	dysfunction	potentially	causing	PD-UU,	specifically	considering	the	prefrontal	area	as	a	control	center	for	decision-making	or	inhibitory	 function	 in	PD	 [13,	 35].	 The	 impairment	 in	 executive	 functioning	 is	 a	 common	and	 early	feature	in	PD	[15],	which	raises	the	question	if	these	specific	functions	might	be	associated	with	urinary	urgency	(with	or	without	incontinence)	in	a	subtype	of	PD	patients.	EF	is	only	sparsely	assessed	within	
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the	MMSE,	which	might	explain	divergent	results	among	previous	studies	evaluating	the	association	between	cognition	and	PD-UU.		Apart	from	the	more	pronounced	executive	worsening,	patients	with	PD-UU	reported	higher	non-motor	symptom	burden.	This	confirms	previous	findings	reporting	non-motor	symptoms	as	highly	prevalent	in	PD	patients	[36]	and	that	PD-UU	patients	experience	higher	rates	of	non-motor	symptoms	than	PD-NUU	 [12,	 31].	 PD	 is	 considered	 a	 spectrum	 disorder,	 whereas	 non-motor	 symptoms	 have	 been	recognized	as	a	progression	marker	of	the	disease	[37,	38].	The	significantly	higher	prevalence	of	non-motor	 symptoms	 in	 the	 PD-UU	 subgroups	 in	 our	 study	 shows	 that	 PD-UU	 might	 influence	 the	experienced	effect	on	PD-UU	and/or	other	non-motor	symptoms	[12].	Indeed,	our	findings	are	in	line	with	previous	studies	that	showed	that	autonomic	dysfunction	should	be	considered	a	risk	factor	for	a	more	 progressive	 course	 of	 PD	 [39,	 40].	 Hence,	 the	 assessment	 of	 various	 non-motor	 symptoms	 is	needed	to	subtype	the	heterogeneity	of	PD	patients.		In	 our	 non-demented	 sample,	 iADL	 function	 did	 not	 contribute	 to	 defining	 the	 status	 of	 PD-UU,	indicating	that	iADL	is	equally	intact	in	both	groups.	Previous	studies	have	shown	that	presence	and	severity	of	urinary	symptoms	might	have	the	potential	to	alter	patients’	everyday	behavior,	mainly	due	to	withdrawal	of	their	social	activities	[5].	Based	on	the	assessment	of	the	FAQ	and	the	ADL	subscale	of	the	PDQ-39,	we	were	not	able	to	support	these	previous	results	[4].	However,	HRQoL	related	to	stigma	differed	between	PD-UU	and	PD-NUU,	but	was	contrary	to	our	expectations.	By	engaging	stigma	arising	from	 health-related	 symptoms,	 studies	 have	 shown	 that	 PD	 patients	 have	 a	 reduced	 interoceptive	sensitivity	[41]	when	compared	to	a	healthy	population.	The	reverse	direction	of	the	stigma	outcome	may	 imply	 that	 PD-UU	 patients	might	 have	 difficulties	 perceiving	 the	 full	 consequences	 of	 urinary	urgency	or	may	tend	to	deny	these	symptoms.	The	interoceptive	sensations	seem	to	be	modulated	by	the	anterior	cingulate	cortex,	a	region	that	has	been	also	associated	with	the	performance	in	executive	tasks	[34,	42].	To	gain	further	insight	into	this	connection,	more	studies	are	required.			In	 line	 with	 previous	 findings	 using	 either	 questionnaires	 or	 urodynamic	 tests,	 our	 PD	 population	presented	a	high	prevalence	of	PD-UU	[2,	12,	43].	Adjusting	for	factors	relating	to	comorbidities	that	may	 play	 a	 role	 in	 developing	 age-related	 bladder	 symptoms,	 we	 minimized	 the	 possible	misclassification	and	concentrated	on	urinary	urgency	as	an	independent	medical	condition	caused	by	PD.	In	our	cohort,	presence	of	PD-UU	was	associated	with	a	longer	disease	duration	and	higher	dosage	of	 LEDD,	which	has	been	previously	 reported	 [4,	 31],	 but	 neither	 to	 age	nor	 gender.	 To	 reduce	 the	possible	statistical	bias,	we	corrected	for	potential	confounders	in	all	steps	of	our	analysis.	Even	though	LEDD	 and	 disease	 duration	 differentiated	 between	 our	 study	 groups,	 they	 did	 not	 contribute	 as	independent	traits	of	PD-UU,	as	their	predictor	value	was	not	significant	in	any	of	our	regression	models.	This	argues	for	our	assumption	that	PD-UU	is	a	symptom	strongly	dependent	upon	the	occurrence	of	other	 non-motor	 symptoms,	 characterizing	 a	 specific	 PD	 subtype.	 PD-UU,	 when	 diagnosed	 as	 an	intrinsic	PD	symptom,	rather	than	age-related	comorbidity,	can	be	an	important	diagnostic	clue	for	the	
	 8 
disease	progression	and	supports	the	existence	of	 the	autonomic	PD	subtype	[37,	44].	However,	 the	neuropathological	pathway	and	its	correlatives	are	not	fully	explained	yet.		Our	study	has	limitations.	The	cross-sectional	study	design	does	not	allow	exploration	of	the	causative	nature	 of	 the	 link	 between	 urinary	 urgency	 and	 cognition	 completely.	 Nevertheless,	 the	 applied	statistical	method	allowed	us	to	assess	objective	classification	to	a	specific	group,	taking	this	limitation	into	concern.	The	non-demented	patients	were	mostly	recruited	from	a	study	that	required	a	lumbar	puncture,	which	could	have	biased	the	recruitment	of	the	participants.	In	general,	we	could	replicate	previous	reported	prevalence	rates	of	PD-UU	and	associations	with	these	phenomena	to	more	advanced	disease	stages.	Secondly,	the	study	had	strict	inclusion	criteria,	which	led	to	a	high	number	of	exclusions.	This	design	was	needed	 to	 investigate	 the	urinary	urgency	caused	by	PD	and	 its	neurodegenerative	deterioration.	 Otherwise,	 the	 presence	 of	 concomitant,	 age-related	 diseases	 causing	 bladder	dysfunction	could	bias	the	results.			In	 conclusion,	 to	 our	 knowledge,	 this	 is	 the	 largest	 study	 that	 investigates	 the	 role	 of	 cognitive	impairment	in	PD-UU	using	a	comprehensive	neuropsychological	test	battery.	Our	findings	emphasize	that	 cognition	 should	 be	 taken	 into	 consideration	 as	 a	 predictor	 for	 urinary	 urgency,	 offering	 an	alternative	opportunity	for	intervention	strategies.		 	
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	Table1	 Demographics	and	clinical	features	of	study	patients		 Total	PD	 PD-NUU	 PD-UU	 p-value	Number	of	Subjects,	n	(%)	 189	(100)	 74	(39.2)	 115	(60.8)	 	Male	gender,	n	(%)	 93	(49.2)	 39	(52.7)	 54	(49.5)	 .29	Age,	years	 64.7	(7.9)	 63.5	(8.3)	 65.5	(7.7)	 .09	Education,	years	 13.4	(2.9)	 13.5	(2.9)	 13.3	(2.8)	 .63	Disease	duration,	years	 5.1	(3.8)	 4.3	(3.6)	 5.6	(3.9)	 .02	LEDD	 506.4(288.5)	 441.1	(273.6)	 548.9	(291.7)	 .01	DAEDD	 166.9	(152.8)	 154.6	(152.2)	 174.8	(153.0)	 .37	PD-MCI	n	(%)	 77	(40.7)	 35	(47.3)	 42	(36.5)	 .21	Motor	Performance	 	 	 	 	UPDRS	III	 24.5	(10.9)	 24.5	(12.7)	 24.6	(9.8)	 .95	Hoehn	&	Yahr,	n	(%)	 	 	 	 .06		 1	 28	(14.8)	 17	(22.9)	 11	(9.5)	 		 2	 110	(58.5)	 38	(51.4)	 72	(62.6)	 		 3	 50	(26.4)	 19	(25.7)	 31	(26.9)	 		 4	 1	(0.3)	 0	(0.0)	 1	(1.0)	 	ARS,	n	(%)	 	 	 	 .35		 0	 66	(34.9)	 31	(41.9)	 35	(30.4)	 		 1	 54	(28.6)	 21	(28.4)	 33	(28.8)	 		 2-3	 45	(23.8)	 14	(18.9)	 31	(26.9)	 		 4+	 24	(12.7)	 8	(10.8)	 16	(13.9)	 	BDI-II	 8.8	(7.22)	 7.7	(6.63)	 9.43	(7.53)	 .13		If	not	other	indicated,	values	are	given	as	mean	and	standard	deviation.	ARS:	Anticholinergic	Risk	Scale;	BDI-II:	Beck	Depression	 Inventory	 II;	LEDD:	Levodopa	equivalent	daily	dose;	DAEDD:	Dopaminergic	antagonist	equivalent	daily	dose	UPDRS-III:	Unified	Parkinson	Disease	Rating	Scale		 	
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	Table	2	 Cognitive	performance	and	non-motor	features	of	study	patients	
Domains	 Total	PD	 PD-NUU	 PD-UU	 Standardized	beta	 95%	CI	 p-value	
Model	A*	 	 	 	 	 	 	Executive	function	 -0.16	(0.92)	 -0.03	(0.93)	 -0.43	(0.90)	 0.51	 [0.84-2.16]	 .04	Attention	 -0.11	(0.76)	 -0.18	(0.75)	 -0.11	(0.76)	 -0.19	 [0.47-1.45]	 .41	Language	 -0.21(0.78)	 -0.18	(0.74)	 -0.27	(0.79)	 0.19	 [0.87-2.23]	 .25	Memory	 -0.25	(0.87)	 -0.39	(0.76)	 -0.16	(0.92)	 0.34	 [0.07,-1.89]	 .68	Visuo-constructive	skills	 -0.34	(0.86)	 -0.43	(0.88)	 -0.28	(0.79)	 0.04	 [0.67-1.61]	 .73	
Model	B*	 	 	 	 	 	 	PDQ-39	Total	Score	 4.2	(3.6)	 3.8	(3.3)	 4.5	(3.7)	 -.13	 [0.76-1.02]	 .14	FAQ	 2.1	(2.1)	 2.0	(2.9)	 2.2	(4.1)	 -0.02	 [0.86-1.12]	 .78	MOCA	 26.30	(3.34)	 26.11	(3.18)	 24.14	(3.18)	 0.15	 [1.04-1.30]	 .007	NMSQuest	 7.7	(4.7)	 5.4	(4.3)	 9.2	(4.4)	 .29	 [1.19-1.51]	 .001	UPDRS	II:	Falls	 0.25	(0.62)	 0.16	(0.46)	 0.34	(0.66)	 0.28	 [0.57-3.24]	 .52	
Model	C*	 	 	 	 	 	 	PDQ-39	Mobility	 17.2	(19.3)	 13.4	(17.3)	 19.6	(20.2)	 .002	 [.98-1.02]	 .89	PDQ-39	ADL	 20.7	(18.3)	 16.7	(16.5)	 23.5	(19.2)	 0.02	 [.99-1.05]	 .09	PDQ-39	Emotional	Well-Being	 17.2	(17.9)	 14.6	(19.5)	 18.7	(18.8)	 .010	 [.98-1.04]	 .48	PDQ-39	Stigma	 14.7	(18.5)	 16.3	(20.6)	 13.6	(17.1)	 -.029	 [.94-99]	 .02	PDQ-39	Social	Support	 10.7	(18.5)	 9.6	(17.2)	 11.4	(19.3)	 -.001	 [.98-1.02]	 .96	PDQ-39	Cognitions	 10.7	(18.4)	 15.2	(15.3)	 29.5	(17.9)	 -.005	 [.98-1.04]	 .64	PDQ-39	Communication	 17.6	(19.3)	 15.8	(18.9)	 18.8	(19.5)	 .013	 [.97-1.02]	 .70	PDQ-39	Bodily	Discomfort	 23.7	(21.8)	 19.5	(20.2)	 26.3	(22.5)	 -.758	 [.99-1.03]	 .18		All	values	are	given	as	z-values:	median	and	standard	deviation;	ADL:	Activity	of	Daily	Living	Function;	FAQ:	Functional	Activities	Questionnaire;	MOCA:	Montreal	Cognitive	Assessment	Test;	NMSQuest:	Non-motor	Symptoms	Questionnaire;	PDQ-39:	Parkinson’s	Disease	Questionnaire;	UPDRS	II:	Unified	Parkinson	Disease	Rating	Scale	II;	*Every	model	also	consisted	of	cofounders,	which	are	not	listed	in	the	table			 	
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	Figure	1	 Recruitment	Flowchart	of	study	groups.		
 	
N	=	189	(72.1%)	Patient	data	analyzed	
N	=	73	(27.9%)	Excluded	for	the	current	analysis		Concomitant	disease	for	bladder	function:			 	 N	=	30		 Benign	prostatic	hyperplasia		 	 N	=	14	 Diabetes	mellitus		 	 N	=	9	 Prostate	cancer		 	 N	=	3	 Neurogenic	Bladder		 	 N	=	2	 Kidney	insufficiency	Medication	interfering	with	cognition		 	 N	=	3	 Anticholinergics		 	 N	=	1	 Methylphenidate	Medication	interfering	with	bladder	function		 N	=	9	 Loop	Diuretics	Other	reasons:			 	 N	=	2	 Inflammatory	marker	in	CSF	
N	=	115	(43.9%)	Patients	reporting	Urinary	Urgency	 N	=	74	(28.2%)	Patients	reporting	no	Urinary	Urgency	
N	=	262	(100%)	Patients	included		into	the	study	
